

INDEXES TO VOLUME 47

Author Index

- Abbruzzese G, 374
Abdullah L, 687
Aberou DN, 137
Agid Y, 137, 655
Aguiglia U, 260
Ajmar F, 374
Akaboshi S, 514
Akiguchi I, 101, 162
Akiyoshi H, 822
Albers GW, 559
Albert ML, 9
Albert MS, 430
Aleck KA, 583
Alessandri MG, 511
Alger JR, 462
Alpéravit A, 648
Alsop DC, 93
Altareci G, 229
Altschuler EL, 553
Alvarez RB, 544
Ames D, 249
Amir RE, 670
Andermann F, 195
Anderson C, 186
Andreassen OA, 447
Andreu AL, 792
Andrias-Kauba S, 765
Ang CW, 314
Annegers JF, 246
Annesi F, 260
Annesi G, 260
Annoni G, 361
Antel JP, 234, 681
Antel SB, 195
Antonini A, 644
Aoyama K, 524
Appollonio I, 641
Archelos JJ, 694
Ariga M, 531
Arnold DL, 179, 195, 234
Arnulf I, 655
Aronen HJ, 353, 470
Ashburner J, 36
Ashe KH, 739
Askanas V, 544
Auer DP, 276
Augood SJ, 201
Auranen M, 666
Austin LM, 9
Avoni P, 395
Azhar S, 229

Back T, 485
Badiali L, 395

Bagalà A, 260
Bagli M, 138, 399
Bajwa ZH, 614
Baldeweg T, 440
Balen AH, 550
Bales K, 739
Balice-Gordon RJ, 596
Bannan JD, 409
Bara-Jimenez W, 377
Baram TZ, 336
Barbiroli B, 838
Barboni P, 395
Barker PB, 477
Barkhof F, 831
Baruzzi A, 395
Bastian AJ, 662
Bates G, 80
Baumgartner MR, 109
Beal MF, 447
Beck H, 26
Becker A, 26
Becker G, 827
Bédard PJ, 570
Beeson D, 504
Begini B, 641
Behle K, 26
Bejjani B-P, 655
Bell JE, 186
Bellet H, 109
Bellone E, 374
Benabid AL, S189
Ben-Ari Y, 729
Benazzou A, S189
Bendl C, 652
Bentz M, 211
Berg D, 827
Berg MJ, 265
Berger GK, 555
Bergman J, 804
Berkovic SF, 265, 557, 840
Bernard V, 137
Bernardi G, S60
Berry-Kravis E, 254
Bertani I, 632
Berthoz A, 819
Beyreuther K, 249
Bianchi MC, 511
Biessmann A, 211
Binkofski F, 553
Bird CR, 583
Biunno I, 361
Blaes F, 504
Blanchet PJ, S70
Blasevich F, 811
Blesa R, 242
Bloch B, 137
Blümcke I, 26
Boiardi A, 137
Bonanni P, 117
Bonilla E, 589, 792
Bonnet A-M, 655
Bono F, 260

Born DE, 113
Bousser MG, 388
Boutière B, 229
Breakefield XO, 369
Brennan JM, 162
Bressman S, 369
Breteler MMB, 145
Brin MF, 369
Brochet B, 831
Brod SA, 127
Bromberg MB, 152
Brooks DG, 659
Brooks DJ, S154
Brotchie JM, S105
Broussolle E, 839
Brown DT, 381
Brown E, 229
Brown R Jr, 46
Brück W, 707
Brunson K, 336
Brunstrom JE, 662
Brust JCM, 415
Bubel S, 269
Burstein R, 614
Busch E, 485

Calabresi P, S60
Calella AM, 632
Calne DB, 493
Calon F, S70
Campbell KP, 152
Canal N, 361
Canales JJ, S53
Canapicchi R, 511
Canevari C, 641
Carcangioli R, 395
Carelli V, 395
Carpenter K, 345
Carrozzo R, 117
Cartwright H, 345
Casadei VM, 361
Cascino G, 246
Cavalcanti F, 260
Caviness JN, 64
Cecillon M, 388
Cendes F, 195
Centonze D, S60
Chaigne D, 840
Chapman J, 257
Chase TN, S122
Chaudhry V, 689
Checcarelli N, 589
Chen K, 336
Chiarelli F, 385
Chinnery PF, 381
Christen S, 329
Christiansen I, 238
Cipriani P, 511
Cocco E, 411
Cody F, 218
Cohn R, 152

Conn PJ, 26
Connolly AM, 792
Cooper JM, 80
Cope TC, 596
Cordato NJ, 718
Cork LC, 596
Cornelio F, 811
Corsini E, 137, 680
Cortelli P, 838
Costa AF, 836
Cotrina ML, 18
Cousens SN, 575
Cowey A, 171
Crain BJ, 412
Crawford F, 687
Crescibene L, 260
Crewes H, 171
Crowther RA, 422
Crusius JBA, 277
Cusmai R, 265

Dahle EJ, 670
Dalakas MC, 46
Dalmau J, 684
Damier P, 655
Darnell RB, 9
De Bellis G, 361
DeGraba T, 229
de Groot JC, 145
De Jong J, 552
de Klerk JBC, 776
de la Fuente-Fernandez R, 493
de Leeuw F-E, 145
de Leon D, 369
DeLong MR, S22
Demeret S, 655
Demirci M, 162
Denckla MB, 477
de Rijk-van Andel JF, 776
de Seze J, 686
Dessaint JP, 686
De Stefano N, 179
Detre JA, 93
Deuschl G, 456
De Vito G, 511
De Vivo DC, 589
Dewar D, 365
Di Blasi C, 811
Dichgans J, 682
Dickwiler G, 462
Diener HC, 238
Dignat-George F, 229
Dillmann W, 782
Di Maria E, 374
DiMauro S, 589, 792
Di Monte DA, S79
Ding L, 409
Di Paolo T, S70
Diringer MN, 416
Di Rocco A, 136

January issue, pp 1-140; February issue, pp 141-280; March issue, pp 281-416; April issue, pp 417-556; May issue, pp 557-690; June issue, pp 691-866.

INDEXES TO VOLUME 47

Author Index

- Abbruzzese G, 374
Abdullah L, 687
Aberou DN, 137
Agid Y, 137, 655
Aguiglia U, 260
Ajmar F, 374
Akaboshi S, 514
Akiguchi I, 101, 162
Akiyoshi H, 822
Albers GW, 559
Albert ML, 9
Albert MS, 430
Aleck KA, 583
Alessandri MG, 511
Alger JR, 462
Alpéravit A, 648
Alsop DC, 93
Altareci G, 229
Altschuler EL, 553
Alvarez RB, 544
Ames D, 249
Amir RE, 670
Andermann F, 195
Anderson C, 186
Andreassen OA, 447
Andreu AL, 792
Andrias-Kauba S, 765
Ang CW, 314
Annegers JF, 246
Annesi F, 260
Annesi G, 260
Annoni G, 361
Antel JP, 234, 681
Antel SB, 195
Antonini A, 644
Aoyama K, 524
Appollonio I, 641
Archelos JJ, 694
Ariga M, 531
Arnold DL, 179, 195, 234
Arnulf I, 655
Aronen HJ, 353, 470
Ashburner J, 36
Ashe KH, 739
Askanas V, 544
Auer DP, 276
Augood SJ, 201
Auranen M, 666
Austin LM, 9
Avoni P, 395
Azhar S, 229

Back T, 485
Badiali L, 395

Bagalà A, 260
Bagli M, 138, 399
Bajwa ZH, 614
Baldeweg T, 440
Balen AH, 550
Bales K, 739
Balice-Gordon RJ, 596
Bannan JD, 409
Bara-Jimenez W, 377
Baram TZ, 336
Barbiroli B, 838
Barboni P, 395
Barker PB, 477
Barkhof F, 831
Baruzzi A, 395
Bastian AJ, 662
Bates G, 80
Baumgartner MR, 109
Beal MF, 447
Beck H, 26
Becker A, 26
Becker G, 827
Bédard PJ, 570
Beeson D, 504
Begini B, 641
Behle K, 26
Bejjani B-P, 655
Bell JE, 186
Bellet H, 109
Bellone E, 374
Benabid AL, S189
Ben-Ari Y, 729
Benazzou A, S189
Bendl C, 652
Bentz M, 211
Berg D, 827
Berg MJ, 265
Berger GK, 555
Bergman J, 804
Berkovic SF, 265, 557, 840
Bernard V, 137
Bernardi G, S60
Berry-Kravis E, 254
Bertani I, 632
Berthoz A, 819
Beyreuther K, 249
Bianchi MC, 511
Biessmann A, 211
Binkofski F, 553
Bird CR, 583
Biunno I, 361
Blaes F, 504
Blanchet PJ, S70
Blasevich F, 811
Blesa R, 242
Bloch B, 137
Blümcke I, 26
Boiardi A, 137
Bonanni P, 117
Bonilla E, 589, 792
Bonnet A-M, 655
Bono F, 260

Born DE, 113
Bousser MG, 388
Boutière B, 229
Breakefield XO, 369
Brennan JM, 162
Bressman S, 369
Breteler MMB, 145
Brin MF, 369
Brochet B, 831
Brod SA, 127
Bromberg MB, 152
Brooks DG, 659
Brooks DJ, S154
Brotchie JM, S105
Broussolle E, 839
Brown DT, 381
Brown E, 229
Brown R Jr, 46
Brück W, 707
Brunson K, 336
Brunstrom JE, 662
Brust JCM, 415
Bubel S, 269
Burstein R, 614
Busch E, 485

Calabresi P, S60
Calella AM, 632
Calne DB, 493
Calon F, S70
Campbell KP, 152
Canal N, 361
Canales JJ, S53
Canapicchi R, 511
Canevari C, 641
Carcangioli R, 395
Carelli V, 395
Carpenter K, 345
Carrozzo R, 117
Cartwright H, 345
Casadei VM, 361
Cascino G, 246
Cavalcanti F, 260
Caviness JN, 64
Cecillon M, 388
Cendes F, 195
Centonze D, S60
Chaigne D, 840
Chapman J, 257
Chase TN, S122
Chaudhry V, 689
Checcarelli N, 589
Chen K, 336
Chiarelli F, 385
Chinnery PF, 381
Christen S, 329
Christiansen I, 238
Cipriani P, 511
Cocco E, 411
Cody F, 218
Cohn R, 152

Conn PJ, 26
Connolly AM, 792
Cooper JM, 80
Cope TC, 596
Cordato NJ, 718
Cork LC, 596
Cornelio F, 811
Corsini E, 137, 680
Cortelli P, 838
Costa AF, 836
Cotrina ML, 18
Cousens SN, 575
Cowey A, 171
Crain BJ, 412
Crawford F, 687
Crescibene L, 260
Crewes H, 171
Crowther RA, 422
Crusius JBA, 277
Cusmai R, 265

Dahle EJ, 670
Dalakas MC, 46
Dalmau J, 684
Damier P, 655
Darnell RB, 9
De Bellis G, 361
DeGraba T, 229
de Groot JC, 145
De Jong J, 552
de Klerk JBC, 776
de la Fuente-Fernandez R, 493
de Leeuw F-E, 145
de Leon D, 369
DeLong MR, S22
Demeret S, 655
Demirci M, 162
Denckla MB, 477
de Rijk-van Andel JF, 776
de Seze J, 686
Dessaint JP, 686
De Stefano N, 179
Detre JA, 93
Deuschl G, 456
De Vito G, 511
De Vivo DC, 589
Dewar D, 365
Di Blasi C, 811
Dichgans J, 682
Dickwiler G, 462
Diener HC, 238
Dignat-George F, 229
Dillmann W, 782
Di Maria E, 374
DiMauro S, 589, 792
Di Monte DA, S79
Ding L, 409
Di Paolo T, S70
Diringer MN, 416
Di Rocco A, 136

January issue, pp 1-140; February issue, pp 141-280; March issue, pp 281-416; April issue, pp 417-556; May issue, pp 557-690; June issue, pp 691-866.

- Dobyns WB, 265
 Dodick DD, 388
 Dolan RJ, 440
 Dommergues M-A, 54
 Donati C, 374, 395
 Donati MA, 792
 Dong-Si T, 652
 Donnelly R, 254
 Dostrovsky J, S141
 Dowd CF, 748
 Driver J, 440
 D'Souza I, 422
 Duara R, 687
 Dube C, 336
 Dubeau F, 179, 195
 Dubowitz V, 143
 Duffau H, 132
 Dufour A, 680
 Duquette P, 234
- Ebersole BJ, 369
 Edan G, 686
 Eggers C, 816
 Eghbal-Ahmadi M, 336
 El Amrani M, 648
 Elger CE, 26
 Ellis P, 238
 Elovaara I, 278
 Engel AG, 162
 Engel WK, 544
 Engelender S, 521
 Eoli M, 137
 Epstein CJ, 447
 Erbguth F, 322
 Esiri MM, 365, 391
 Espeel M, 109
 Estibeiro K, 575
 Eto Y, 624
 Evangelou N, 391
 Evrard P, 54
 Ezquerre M, 242
- Fadda E, 411
 Fagan AM, 739
 Fahn S, S2
 Fardeau M, 666
 Farina L, 811
 Farmer JM, 659
 Ferrante RJ, 447
 Ferrarese C, 641
 Ferrari MD, 238
 Ferri C, 361
 Ferriero DM, 329
 Feucht HH, 816
 Filion M, S35
 Filippi M, 831
 Fink GR, 440
 Fink S, 369
 Fischbeck KH, 659
 Flanagan KM, 152
 Forloni G, 632
 Fornai F, 511
 Forsgren L, 369
 Förstl H, 399
 Fourmaintraux A, 109
 Fox NC, 419
- Frackowiak RSJ, 36
 Franceschi M, 361
 Francis MJ, 827
 Frangione B, 544
 Frasson E, 374
 Frattola L, 641
 Freeman DW, 87
 Freeman M, 687
 French Alzheimer's Disease Study Group, 688
 Freund H-J, 553
 Friedman J, 369
 Frigerio S, 137
 Frigo M, 641
 Frohman EM, 843
 Fronto-Temporal Dementia Genetics Study, 688
 Fujigasaki H, 550
 Fujikawa Y, 524
 Fukuma G, 822
 Funato T, 274
 Furukawa Y, 517
- Gabizon R, 257
 Gaiarsa J-L, 729
 Gálvez-Jiménez N, 837
 Gambardella A, 260
 Gamero MA, 836
 Gaymard B, 819
 Geiger JD, 186
 Gelati M, 137, 680
 Genton P, 550
 Gerfen CR, 842
 Ghiso J, 544
 Giacomini P, 560
 Gibbons RJ, 117
 Giovannoni G, 684
 Giroux M, S131
 Glaze DG, 670
 Gleeson JG, 265
 Goedert M, 422
 Goetz CG, 404
 Gold M, 687
 Goldman J, 596
 Goldman SA, 18
 Gomez-Isla T, 430
 Gonazalez-Gomez I, 152
 González-Moreno JM, 836
 Goodyer ID, 827
 Goor-Aryeh I, 614
 Gössl C, 276
 Goulet M, S70
 Govin YP, 462
 Graf WD, 113
 Grafstein B, 18
 Graham DI, 365
 Grant PE, 265
 Grau AJ, 652
 Grauer MT, 408
 Graus F, 684
 Graybiel AM, S53
 Greco R, 385
 Green AJE, 575
 Greenlee JE, 4
 Greer JM, 685
 Gressens P, 54
- Griffin WST, 361, 365
 Griggs RC, 46
 Grimaldi LME, 361
 Grimes D, 369
 Grisoli M, 104
 Grond-Ginsbach C, 652
 Grondin R, S70
 Grossman M, 93
 Grünewald S, 776
 Guerrini R, 117, 265
 Guicheney P, 811
 Guimaraes J, 792
 Günther I, 644
 Guo FL, 589
 Gurvich N, 369
 Guttman M, 517
- Haaß A, 408
 Haaparanta M, 804
 Haas J, 211
 Hadjigeorgiou GM, 792
 Hahn AF, 46
 Hahn CD, 792
 Halbach VV, 748
 Hallett M, S147, 377, 456
 Halliday GM, 718, 345
 Hallupp M, 249
 Hamano H, 792
 Hammans S, 792
 Hanai T, 822
 Hänninen T, 470
 Hara K, 782
 Harding AJ, 718
 Harding GFA, 275
 Hargreave M, 837
 Hart PE, 80
 Hartung H-P, 694
 Hasegawa H, 422
 Hasegawa M, 422
 Hashizume Y, 122
 Hattori H, 136
 Haughey NJ, 186
 Hauser WA, 246
 Hawkes C, 682
 Hayasaka K, 101, 514
 Hayase N, 524
 Heidenreich F, 162
 Heidenreich RA, 583
 Hely MA, 718
 Henderson JM, 345
 Henretta T, 776
 Herrlinger U, 682
 Hesdorffer DC, 246
 Hettiarachchi J, 238
 Heun R, 138, 399
 Higashida RT, 748
 Higgs DR, 117
 Higuchi Y, 136
 Hildt U, 652
 Hirano I, 792
 Hirano M, 589, 792
 Hirata K, 314
 Hirose S, 822
 Hirsch EC, S115, 137
 Hodges JR, 36
 Hodgson TL, 171
- Hoehn M, 485
 Hoffmann LA, 211
 Hofman A, 145
 Holden JE, 493
 Holloway LW, 113
 Holmes GL, 729
 Holmgren G, 369
 Holtzman DM, 739
 Holzer G, 408
 Honma T, 514
 Hoption Cann SA, 408
 Hossmann K-A, 485
 Houeto J-L, 655
 Howard D, 171
 Huijbens K, 776
 Hutchison W, S141
 Huttenlocher PR, 265
 Hutton M, 417
 Huttunen J, 353
 Hyland K, 517
 Hyman BT, 430, 739
- Ikezoe K, 531
 Ilmoniemi RJ, 353
 Imbach T, 776
 Imoto C, 531
 Inoue T, 822
 Invernizzi R, 632
 Inzitari D, 141
 Irie S, 274
 Irizarry MC, 739
 Ironside JW, 575
 Isojärvi JIT, 551
 Israel I, 819
 Ito A, 514
 Itoh K, 122
 Iwabuchi K, 550
 Iwata H, 822
 Iwatubo T, 422
 Izquierdo G, 836
 Izumi Y, 528
- Jackson GD, 557
 Jacobs BC, 314
 Jacobson S, 306
 Jaeken J, 776
 Jahan R, 462
 Jakobs C, 109, 540
 Jakowec M, S79
 Jansen GA, 109
 Jenkinson M, 606
 Jenner P, S1, S90
 Jessen F, 138
 Johansen-Berg H, 606
 Johnson RT, 1, 843
 Johnston MV, 556
 Jolesz F, 430
 Jolles J, 145
 Jones K, 430
 Jones M, 186
 Joutel A, 388
 Juhng KN, 306
 Jüttler E, 652
- Kaasinen V, 804
 Kahana E, 257

- Kalafut M, 462
 Kalino H, 666
 Kameyama M, 528
 Kanazawa N, 274, 624
 Kaneko S, 822
 Kanemoto K, 571
 Kaplan P, 589
 Karadimas C, 589
 Kato H, 801
 Kato M, 275, 514
 Kaufmann WE, 412, 477
 Kawakami H, 528
 Kawamata T, 422
 Kawarai T, 528
 Kawasaki J, 571
 Kazuta T, 528
 Kei G, 684
 Kemp WH, 286
 Kerr L, 152
 Kerrigan JF, 583
 Kidwell CS, 462
 Kikinis R, 430
 Kilimann MW, 536
 Killestein J, 277
 Killiany RJ, 430
 Kira J-i, 624
 Kirchner H, 269
 Kish SJ, 517
 Klein AM, 447
 Klein C, 369
 Kleinermans D, 238
 Klivenyi P, 447
 Knight RSG, 575
 Knip M, 551
 Kobayashi S, 524
 Koga M, 314
 Kohno K, 485
 Koivula T, 278
 Kok JG, 238
 Kokubo Y, 782
 Koltzenburg M, 827
 Komure O, 528
 Kondo N, 836
 Körönönen M, 470
 Korczyn AD, 257
 Kornhuber J, 399
 Korth CW, 477
 Koudsie A, S189
 Koyano S, 550
 Krack P, S189
 Kramer PL, 369
 Kuhn R, 26
 Kümpfel T, 276
 Küning G, 644
 Kurokawa T, 822
 Kurz A, 399
 Kwok JBJ, 249
 Kyllerman M, 369

 Laakso M, 470
 Labalette M, 686
 LaGanke CC, 87
 Lai M, 411
 Lang AE, S141, S193, 369, 517
 Lang B, 504

 Langston JW, S79, 280
 Laribi O, 137
 Lassmann H, 707
 Lauria G, 104
 Lautenschlager N, 399
 Layh-Schmitt G, 652
 Leahy WR, 555
 Lee CS, 493
 Lee M, 606
 Leenders KL, 322, 644
 Leff AP, 171
 Lefler JE, 748
 Lehéricy S, 132
 Lehtimäki T, 278
 Leib SL, 329
 Leist TP, 306
 Lemperi TE, 748
 Lennon VA, 297
 Leonard C, 152
 Leppert M, 152
 Leung J, 369
 Levey AI, 137
 Levy R, S141
 Li LM, 195
 Li Q-X, 249
 Licastro F, 361
 Lichtarge O, 670
 Lie AA, 26
 Limousin P, S189
 Lin C, 101
 Lindsey JW, 127
 Liu S, 18
 Lobel P, 254
 Lodi R, 381, 838
 Love S, 365
 Lozano AM, S141
 Lucas M, 836
 Lucchinetti C, 707
 Ludwin SK, 691
 Luo RF, 265
 Luomala M, 278
 Lupski JR, 6
 Lynch DR, 659

 Maass M, 408
 Maaswinkel-Mooij P, 540
 MacGowan S, 365
 Mackenzie J, 575
 Mackey B, 739
 Macleod MA, 575
 Magyar-Lehmann S, 322
 Mahal A, 80
 Maier W, 138, 399
 Maillard I, 792
 Malafosse A, 840
 Malek AM, 748
 Malicki DM, 670
 Malin J-P, 536
 Malitschek B, 26
 Mancosu C, 411
 Mandich P, 374
 Mangiarini L, 80
 Manners D, 381
 Marchese R, 374
 Mariani C, 361
 Marín C, 684

 Marroso MG, 411
 Martí MJ, 242
 Mascher B, 269
 Massa G, 680
 Masters CL, 249
 Matsubara K, 524
 Matsuishi T, 801
 Matthews PM, 391, 606
 Matthijs G, 776
 Mattiello J, 462
 McCarron R, 229
 McDermott MP, 46
 McDonald WI, 831
 McFarland HF, 306
 McGuinness MC, 286
 McManis PG, 46
 McMorrin PD, 71
 Melms A, 682
 Mendell JR, 46
 Mestril R, 782
 Meyer P, 254
 Meyers PM, 748
 Michaelis RC, 113
 Mies G, 485
 Miller DH, 831
 Miller DW, 201
 Milone M, 162
 Minami N, 531
 Minassian BA, 666
 Mink JW, 662
 Mitchell WM, 409
 Mitsudome A, 275, 822
 Miura N, 827
 Miyamoto T, 571
 Mizuguchi M, 756
 Momoi T, 531
 Monari L, 395
 Montagna P, 374, 395, 838
 Montalban X, 831
 Mooyer PAW, 109
 Mora M, 811
 Morandi L, 811
 Morgenthaler M, 408
 Morgese G, 385
 Mori K, 801
 Mori S, 412
 Morino H, 528
 Morissette M, S70
 Morris JGL, 718
 Morris PR, 684
 Moseley ME, 559
 Moser AB, 286
 Moss M, 430
 Moss T, 365
 Motil KJ, 670
 Mouillard B, 840
 Mrak RE, 365
 Mulhern RK, 280
 Mullan M, 687
 Mulley JC, 840
 Mummer CJ, 36
 Munoz DG, 374
 Muñoz E, 242
 Muntoni F, 666
 Muranaka H, 822
 Muriel M-P, 137
 Murray LS, 365

 Nagahiro Y, 524
 Nakamura A, 550
 Nakamura S, 528
 Nakano S, 162
 Nanba E, 514
 Nath A, 186
 Naumann M, 322, 827
 Nedergaard M, 18
 Neumann-Haefelin T, 559
 Nicoll JAR, 365
 Nihei K, 531
 Nishimura M, 571
 Nishino I, 792
 Nitsch R, 26
 Nonaka I, 531, 792
 Nukada H, 71
 Numakura C, 101
 Nurmi E, 804
 Nutt JG, S160
 Nygaard TG, 792

 Obayashi H, 571
 Obeso JA, S1, S22, S167
 O'Boyle D, 218
 Oda M, 528
 Ogino M, 274
 Oh JD, S122
 Ohashi T, 624
 Ohno K, 162
 Ohtaki E, 801
 Oka A, 756
 Oka N, 101
 Olanow CW, S1, S22, S167
 Olesen J, 238
 Oliva R, 242
 Oliveri RL, 260
 Olivier A, 195
 Onkenhout W, 540
 Oudkerk M, 145
 Oyanagi K, 122
 Ozelius LJ, 369

 Pal PK, 493
 Palace J, 391, 606
 Pallotti F, 589
 Papadimitriou A, 792
 Papadopoulos LC, 589
 Papassotiropoulos A, 138, 399
 Pareyson D, 104, 811
 Parisi JE, 388, 707
 Partanen K, 470
 Pasqua AA, 260
 Pasquinelli G, 260
 Pastor P, 242
 Patkai J, 54
 Patterson K, 36
 Paul SM, 739
 Pauls J, 399
 Pearson GD, 412
 Peeters EAJ, 540
 Pelletier D, 234
 Peña AS, 277
 Pender MP, 685
 Pendlebury S, 606

- Penney JB Jr, 201
 Percy AK, 670, 690, 801
 Pérez C, 277
 Petzinger G, S79
 Pfister LA, 329
 Phatouros CP, 748
 Philippi A, 670
 Piallat B, S189
 Piccini P, S154
 Pierrot-Deseilligny C, 819
 Pifarré A, 684
 Pihlajamäki M, 470
 Pinter MJ, 596
 Piolti R, 641
 Plaschke M, 26
 Plested P, 504
 Pollak P, S189
 Pollard JD, 765
 Polman CH, 277, 831
 Poole PH, 238
 Poorkaj P, 422
 Pouwels PJW, 540
 Pramstaller PP, 374
 Prat A, 234, 681
 Pratley RE, 64
 Preux P-M, 808
 Price CJ, 36
 Prioleau C, 369
 Ptacek LJ, 46
 Pugliatti M, 411

 Quattrone A, 260
 Quik M, S79

 Rajdev S, 782
 Rammohan KW, 842
 Ransil BJ, 614
 Rao ML, 138
 Rapin I, 415
 Rascol O, S179
 Ravussin E, 64
 Raymond D, 369
 Reddy H, 606
 Reiners K, 322, 827
 Renauld J-C, 54
 Ricci S, 265
 Riikonen R, 801
 Rinne JO, 804
 Rivaud-Péchoux S, 819
 Rivera JP, 279
 Rizzo WB, 281
 Robert L, 648
 Rodriguez M, S22, 707
 Rodriguez-Oroz MC, S22
 Roels F, 109
 Roine RO, 353
 Roon KI, 238
 Rorden C, 440
 Rosenmann H, 257
 Ross CA, 521
 Rossor MN, 419
 Rouleau GA, 517
 Rowland LP, 792
 Rubio-Gozalbo ME, 552,
 776
 Ruottinen HM, 804

 Russell JA, 792
 Ruth TJ, 493
 Rye DB, 842

 Sadatipour BT, 685
 Saito M, 801
 Saito T, 274, 624
 Saito Y, 756
 Saiz A, 684
 Sakuraba H, 122
 Salbe AD, 64
 Salmaggi A, 137, 680
 Salonen O, 353
 Samii A, 493
 Samuel M, S154
 Sanchez-Pernaute R, 644
 Sandor T, 430
 Sanger TD, 377
 Sanner G, 369
 Sapppay-Marinier D, 839
 Sartorius L, 739
 Sato T, 122
 Saudubray JM, 109
 Saunders-Pullman R, 369
 Saver JL, 462
 Schafft T, 816
 Schapira AHV, 80
 Scheffer IE, 265, 840
 Scheithauer B, 707
 Schellenberg GD, 422
 Scherer SW, 666
 Schiffmann R, 229
 Schinka J, 687
 Schlenke P, 269
 Schmitz B, 485
 Schnitzler P, 652
 Schofield PR, 249
 Schramm J, 26
 Schrijver HM, 277
 Schröder JM, 536
 Schultz R, 670
 Schulzer M, 493
 Schumann EM, 276
 Scott SK, 171
 Sealoff SC, S12, 369
 Seitz RJ, 553
 Semrad CE, 792
 Sena-Esteves M, 369
 Serles W, 195
 Sghiranzoni A, 104, 811
 Shahanan JL, 117
 Shanske S, 589
 Shapiro BC, 46
 Sharp FR, 782
 Sharpe JA, 689
 Shaw DWW, 113
 Shaw S, 329
 Shelton P, 377
 Shen X-M, 162
 Shiihara T, 514
 Shimadzu M, 517
 Shimizu J, 71
 Shimizu K, 524
 Shimmoto M, 122
 Shimozawa N, 836
 Shin YS, 536

 Shinobu LA, 447
 Shiono H, 524
 Shirley A, 596
 Shoubridge EA, 179
 Sichez J-P, 132
 Siegler I, 819
 Silvani A, 137
 Simon ES, 257
 Sindern E, 536
 Sindou P, 808
 Sinkkonen J, 353
 Sleat DE, 254
 Smeitink JAM, 552
 Smith DBJ, 596
 Smith EO, 670
 Smith KD, 286
 Smith S, 391, 606
 Sohar I, 254
 Soininen H, 470
 Solaiyappan M, 412
 Solano F, 836
 Solano SM, 201
 Soldan SS, 306
 Solin O, 804
 Soltesz I, 336
 Sorbi S, 361
 Sossi V, 493
 Spadafora P, 260
 Sparagana SP, 517
 Spector SA, 46
 Spillantini MG, 422
 Spinazzola A, 792
 Sriram S, 409
 Starkman S, 462
 Steck A, 808
 Steen RG, 280
 Steiner I, 792
 Stellbrink HJ, 816
 Stephan C, 408
 Stevenson VL, 831
 Stewart GE, 575
 Stewart J, 365
 Stieljes B, 412
 Stille W, 408
 Stöckler-Ipsiroglu S, 540
 Stoessl AJ, 493
 Storch MK, 694
 Storch-Hagenlocher B, 211
 Stratton CW, 409
 Stroink H, 776
 Strunk T, 269
 Stuerenburg HJ, 816
 Styles P, 381
 Sue CM, 589
 Suzuki Y, 836

 Tabaraud F, 808
 Tabaton M, 374
 Tabrizi SJ, 80
 Tadesse S, 792
 Takahashi H, 122, 521
 Takamatsu J, 422
 Takashima S, 756
 Tan E, 162
 Tanaka C, 422
 Tanila H, 470

 Tanimukai S, 422
 Tanji K, 589
 Tanzi RE, 283, 430
 Tapanainen JS, 551
 Tarby TJ, 583
 Tarcic N, 680
 Täuber MG, 329
 Tawil R, 46
 Taylor DJ, 381
 Taylor J, 765
 Tenkova T, 739
 Terry RD, 421
 Thaler F, 632
 Tharp A, 409
 Thomas JR, 113
 Thompson AJ, 831
 Timar L, 670
 Tobimatsu S, 275
 Tolosa E, 242, 684
 Tomoda Y, 275
 Toro C, 456
 Tosetti M, 511
 Tournier-Lasserre E, 388
 Tran CQ, 670
 Treib J, 408
 Trenkwalder C, 276
 Treves TA, 257
 Trugman JM, 517
 Tsuburaya K, 514
 Tsuji M, 136
 Tsuji S, 521
 Tsujino S, 624
 Tsuruda J, 152
 Tsutsumi M, 822
 Tureen JH, 329
 Turjanski N, S154
 Tzourio C, 648

 Uchihara T, 550
 Udaka F, 528
 Uitdehaag BMJ, 277
 Umegae N, 524

 Vainionpää LK, 551
 Valentino P, 260
 Vallat J-M, 808
 Van Coster R, 589
 Vandenberghe A, 808
 Van den Veyter IB, 808
 van der Knaap MS, 540
 van der Meché FGA, 314
 van Doorn PA, 314
 van Gijn J, 145
 Van Hove JLK, 776
 van Lunzen J, 816
 van Netten C, 408
 van Netten JP, 408
 van Zijl PCM, 412
 Varani G, 422
 Varani L, 422
 Veglia F, 361
 Verhagen A, 644
 Verhoeven NM, 109, 540
 Verloes A, 792
 Vermersch P, 686
 Vernino S, 297

- Verrips A, 552, 776
Verrotti A, 385
Vespa P, 462
Vidal R, 544
Vieregge P, 369
Vighetto A, 839
Vignier N, 811
Vigo T, 374
Villanova M, 666
Villeneuve N, 729
Vincent A, 162, 504
Vinuela F, 462
Vitek JL, S131
Vogt-Schaden ME, 211
Vontobel P, 644
Vorgerd M, 536
Vu TH, 792
- Wada K, 822
Wahlström J, 369
Wakabayashi K, 521
Wallace RH, 840
Walsh CA, 265
- Walsh P, 162
Wanders RJA, 109
Wandinger K-P, 269
Wang PY, 477
Wang WC, 280
Wei H, 286
Weinstein PR, 782
Weishaupt A, 827
Weiss HD, 140
Weller M, 682
Wendel U, 776
Werner P, 136
Wevers RA, 776
Wheless JW, 265
Whitaker JN, 87
Whyte S, 249
Wiestler OD, 26
Wikström H, 353
Wilcock G, 365
Wildemann B, 211
Will RG, 575
Willemsen MAAP, 552
Willoughby JO, 416
- Wilson RB, 659
Wise RJS, 171
Woessner R, 408
Wolinsky JS, 127
Wong M, 662
Working Group on Periodic Paralysis, 46
Workman J, 80
Wudel J, 493
Wyatt P, 517
- Xiong X, 280
- Yagishita S, 550
Yamada S, 801
Yamada T, 624
Yamamoto T, 274
Yamashita Y, 801
Yan C, 531
Yan WX, 765
Yang X-L, 827
Yao S-y, 409
Yarnitsky D, 614
- Yasuda M, 422
Yonetani M, 822
Yoshimoto M, 521
Young AB, 201
Yuki N, 274, 314
- Zange J, 536
Zanusso G, 374
Zappia M, 260
Zayas MD, 836
Zeidler M, 575, 683
Zenri F, 822
Zhang P, 152
Zhang YM, 275
Zhang Z, 836
Zia S, 218
Ziegler DK, 140
Ziemssen F, 536
Zifkin BG, 179
Zilber N, 257
Zoghbi HY, 670
Zoia C, 641
Zöllner B, 816

Subject Index

Acetylcholine

IgG from "seronegative" myasthenia gravis patients binds to a muscle cell line, TE671, but not to human acetylcholine receptor (Blaes et al) 2000;47:504

Acetylcholinesterase

spectrum of mutations causing end-plate acetylcholinesterase deficiency (Ohno et al) 2000;47:162

Activated T-cells; *see* T-lymphocytes

Adhesions

in vitro glatiramer acetate treatment of brain endothelium does not reduce adhesion phenomena (Dufour et al) (Letter); (Dufour et al) (Reply) 2000;47:680

Adrenoleukodystrophy

peroxisome 1, 2, 3 ... (Rizzo) 2000;47:281 (Editorial)
pharmacological induction of peroxisomes in peroxisome biogenesis disorders (Wei et al) 2000;47:286

simvastatin and plasma very-long-chain fatty acids in X-linked adrenoleukodystrophy (Verrips et al) 2000;47:552 (Letter)

Age factors

Creutzfeldt-Jakob disease profile in patients homozygous for the PRNP E200K mutation (Simon et al) 2000;47:257

Aged

cerebral white matter lesions and cognitive function: the Rotterdam Scan Study (de Groot et al) 2000;47:145
major depression is a risk factor for seizures in older adults (Hesdorffer et al) 2000;47:246

Agnosia

mirror agnosia: the Ramachandran sign (Altschuler) (Letter); (Binkofski et al) (Reply) 2000;47:553

Alexia; *see* Dyslexia, acquired

Alkalosis

penumbral tissue alkalosis in focal cerebral ischemia: relationship to energy metabolism, blood flow, and steady potential (Back et al) 2000;47:485

Alleles

inclusion body myositis, muscle blood vessel and cardiac amyloidosis, and transthyretin Val122Ile allele (Askanas et al) 2000;47:544

Allodynia

association between migraine and cutaneous allodynia (Burstein et al) 2000;47:614

Alpha macroglobulins

gene-gene interaction between interleukin-6 and α_2 -macroglobulin influences the risk for Alzheimer's disease (Bagli et al) 2000;47:138 (Letter)

Alpha-synuclein; *see* Synuclein

Alzheimer's disease, diagnosis

mere forgetfulness or early Alzheimer's disease? (Rossor and Fox) 2000;47:419 (Editorial)

use of structural magnetic resonance imaging to predict who will get Alzheimer's disease (Killiany et al) 2000;47:430

Alzheimer's disease, genetics

Alzheimer's disease risk and the interleukin-1 genes (Tanzi) 2000;47:283 (Editorial)

association of early-onset Alzheimer's disease with an interleukin-1 α gene polymorphism (Grimaldi et al) 2000;47:361

association of interleukin-1 gene polymorphisms with Alzheimer's disease (Nicoll et al) 2000;47:365

gene-gene interaction between interleukin-6 and α_2 -macroglobulin influences the risk for Alzheimer's disease (Bagli et al) 2000;47:138 (Letter)

genetic variation of cathepsin D is a major risk factor for Alzheimer's disease (Papassotiropoulos et al) 2000;47:399

no association between the NOS3 codon 298 polymorphism and Alzheimer's disease in a sample from the United States (Crawford et al) 2000;47:687 (Letter)

Alzheimer's disease, pathology

apoE facilitates neuritic and cerebrovascular plaque formation in the APPsw mouse model of Alzheimer's disease (Holtzman et al) 2000;47:739

assessment of cerebral blood flow in Alzheimer's disease by spin-labeled magnetic resonance imaging (Alsop et al) 2000;47:93

glutamate uptake is decreased in platelets from Alzheimer's disease patients (Ferrarese et al) 2000;47:641

novel Leu723Pro amyloid precursor protein mutation increases amyloid β 42(43) peptide levels and induces apoptosis (Kwok et al) 2000;47:249

regional brain atrophy in progressive supranuclear palsy and Lewy body disease (Cordato et al) 2000;47:718

where in the brain does Alzheimer's disease begin? (Terry) 2000;47:421 (Editorial)

Ammonia

three novel mutations (G27E, insAAC, R179X) in the ORNT1 gene of Japanese patients with hyperornithinemia, hyperammonemia, and homocitrullinuria syndrome (Tsujino et al) 2000;47:624

Amyloid beta-protein precursor

novel Leu723Pro amyloid precursor protein mutation increases amyloid β 42(43) peptide levels and induces apoptosis (Kwok et al) 2000;47:249

Amyloidosis

inclusion body myositis, muscle blood vessel and cardiac amyloidosis, and transthyretin Val122Ile allele (Askanas et al) 2000;47:544

Amyotrophic lateral sclerosis

partial deficiency of manganese superoxide dismutase exacerbates a transgenic mouse model of amyotrophic lateral sclerosis (Andreassen et al) 2000;47:447

Anemia, sickle cell

subtle brain abnormalities in children with sickle cell disease: relationship to blood hematocrit (Rivera) (Letter); (Steen et al) (Reply) 2000;47:279

Aneurysm

hemorrhagic complications in vein of Galen malformations (Meyers et al) 2000;47:748

Angiography

new magnetic resonance imaging methods for cerebrovascular disease: emerging clinical applications (Neumann-Haefelin et al) 2000;47:559 (Neurological progress)

Angioma; *see* Hemangioma

Annals of Neurology

message from the editor (Johnson) 2000;47:1 (Editorial)

Antibiotics

Chlamydia, Rickettsia, and antibiotic treatment of multiple sclerosis (Hoption Cann et al) (Letter); (Sriram et al) (Reply) 2000;47:408

Antibodies

circulating antiganglioside antibodies are not associated with the development of progressive disease or cerebral atrophy in patients with multiple sclerosis (Giovannoni et al) (Letter); (Sadatipour et al) (Reply) 2000;47:684 clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1 ganglioside (Yuki et al) 2000;47:314

new Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity (Vernino and Lennon) 2000;47:297

no cytomegalovirus DNA in sera from patients with anti-MAG/SGPG antibody-associated neuropathy (Irie et al) (Letter); (Yamamoto and Yuki) (Reply) 2000;47:274

Antiretroviral therapy; see Retroviridae

Apolipoprotein E

apoE facilitates neuritic and cerebrovascular plaque formation in the APPsw mouse model of Alzheimer's disease (Holtzman et al) 2000;47:739

Apomorphine

neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine (Lozano et al) 2000;47:S141

Apoptosis; see Cell death

Arteriovenous malformations

hemorrhagic complications in vein of Galen malformations (Meyers et al) 2000;47:748

intraoperative unmasking of brain redundant motor sites during resection of a precentral angioma: evidence using direct cortical stimulation (Duffau et al) 2000;47:132

Astrocytes

meningeal cells can communicate with astrocytes by calcium signaling (Grafstein et al) 2000;47:18

Ataxia

increased serum transferrin receptor concentrations in Friedreich ataxia (Wilson et al) 2000;47:659

magnetic resonance spectroscopy of episodic ataxia type 2 and migraine (Montagna et al) (Letter); (Sappéy-Marinier et al) (Reply) 2000;47:838

Atrophy

circulating antiganglioside antibodies are not associated with the development of progressive disease or cerebral atrophy in patients with multiple sclerosis (Giovannoni et al) (Letter); (Sadatipour et al) (Reply) 2000;47:684

regional brain atrophy in progressive supranuclear palsy and Lewy body disease (Cordato et al) 2000;47:718

voxel-based morphometry study of semantic dementia: relationship between temporal lobe atrophy and semantic memory (Mummery et al) 2000;47:36

Autoantibodies

role of B cells and autoantibodies in multiple sclerosis (Archelos et al) 2000;47:694 (Neurological progress)

Autoimmune diseases

combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN- α) does not improve experimental autoimmune encephalomyelitis (Brod et al) 2000;47:127

passive transfer of demyelination by serum of IgG from CIDP patients (Yan et al) 2000;47:765

Autoimmunity

new Purkinje cell antibody (PCA-2): marker of lung can-

cer-related neurological autoimmunity (Vernino and Lennon) 2000;47:297

Axons

quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis (Evangelou et al) 2000;47:391

Azathioprine

association of primary central nervous system lymphoma with long-term azathioprine therapy for myasthenia gravis? (Herrlinger et al) 2000;47:682 (Letter)

Bacterial infections

Chlamydia, Rickettsia, and antibiotic treatment of multiple sclerosis (Hoption Cann et al) (Letter); (Sriram et al) (Reply) 2000;47:408

Basal ganglia

congenital encephalomyopathy with epilepsy, chorioretinitis, basal ganglia involvement, and muscle minicores (Avoni et al) 2000;47:395

corticobasal degeneration shares a common genetic background with progressive supranuclear palsy (Di Maria et al) 2000;47:374

physiologic basis of dyskinesia (Filion) 2000;47:S35

Behavior

mental retardation and behavioral problems as presenting signs of a creatine synthesis defect (van der Knaap et al) 2000;47:540

patterns of gene expression and behavior induced by chronic dopamine treatments (Canales and Graybiel) 2000;47:S53

Benign familial neonatal convulsions; see Convulsions

Benzodiazepines

benzodiazepine receptor binding in Huntington's disease: [11 C]flumazenil uptake measured using positron emission tomography (Künig et al) 2000;47:644

Blood platelets

glutamate uptake is decreased in platelets from Alzheimer's disease patients (Ferrarese et al) 2000;47:641

B-lymphocytes

role of B cells and autoantibodies in multiple sclerosis (Archelos et al) 2000;47:694 (Neurological progress)

Bone

increased bone turnover in epileptic patients treated with carbamazepine (Verrotti et al) 2000;47:385

Books

The Autonomic Nervous System and Its Effectors, by Brading (Willoughby) 2000;47:416

The Clinical Neuropsychiatry of Multiple Sclerosis, by Feinstein (Johnson) 2000;47:843

Critical Care Neurology, edited by Miller and Raps (Diringer) 2000;47:416

Diagnostic Testing in Neurology, by Evans (Leahy) 2000;47:555

Diamond and Dalessio's The Practicing Physician's Approach to Headache, 6th ed, edited by Diamond and Solomon (Weiss) 2000;47:140

Dizziness, Hearing Loss, and Tinnitus, by Baloh (Sharpe) 2000;47:689

Handbook of Neurodevelopmental and Genetic Disorders in Children, edited by Goldstein and Reynolds (Rapin) 2000;47:415

Jasper's Basic Mechanisms of the Epilepsies, 3rd ed, *Advances in Neurology*, Vol 79, edited by Delgado-Escueta et al (Bergy) 2000;47:555

Migraine and Headache Pathophysiology, edited by Edvinsson (Ziegler) 2000;47:140

- Neurology of Bladder, Bowel, and Sexual Dysfunction*, edited by Fowler (Frohman) 2000;47:843
- Neurology of the Inflammatory Connective Tissue Diseases*, by Jennekens and Kater (Rammohan) 2000;47:842
- Occupational and Environmental Neurotoxicology*, by Feldman (Brust) 2000;47:415
- Organelle Diseases: Clinical Features, Pathogenesis, and Management*, edited by Applegarth et al (Percy) 2000; 47:690
- Pediatric Neurology: Principles and Practice*, by Swaiman and Ashwal (Johnston) 2000;47:556
- Review of Electromyography in Clinical Practice: A Case Study Approach*, by Katirji (Chaudhry) 2000;47:689
- Sleep Medicine*, by Aldrich (Rye) 2000;47:842
- Brain, blood supply**
- assessment of cerebral blood flow in Alzheimer's disease by spin-labeled magnetic resonance imaging (Alsop et al) 2000;47:93
 - endothelin inhibition improves cerebral blood flow and is neuroprotective in pneumococcal meningitis (Pfister et al) 2000;47:329
 - penumbral tissue alkalosis in focal cerebral ischemia: relationship to energy metabolism, blood flow, and steady potential (Back et al) 2000;47:485
- Brain, metabolism**
- reversible brain creatine deficiency in two sisters with normal blood creatine level (Bianchi et al) 2000;47:511
- Brain injuries**
- motor cortex shows adaptive functional changes to brain injury from multiple sclerosis (Lee et al) 2000;47:606
- CADASIL**
- de novo mutation in the *Notch3* gene causing CADASIL (Joutel et al) 2000;47:388
- Calcium**
- meningeal cells can communicate with astrocytes by calcium signaling (Grafstein et al) 2000;47:18
- Carbamazepine**
- increased bone turnover in epileptic patients treated with carbamazepine (Verrotti et al) 2000;47:385
- Carbonic anhydrase inhibitors**
- randomized trials of dichlorphenamide in the periodic paralyses (Tawil et al) 2000;47:46
- Carcinoma, oat cell**
- new Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity (Vernino and Lennon) 2000;47:297
- Cardiac amyloidosis; see Amyloidosis**
- Caspase**
- novel congenital myopathy with apoptotic changes (Ikezoe et al) 2000;47:531
- Catalase**
- atypical Refsum disease with pipecolic acidemia and abnormal catalase distribution (Baumgartner et al) 2000; 47:109
- Cathepsin D**
- genetic variation of cathepsin D is a major risk factor for Alzheimer's disease (Papassotiropoulos et al) 2000;47: 399
- Cavernous angioma; see Hemangioma**
- Cell adhesion molecules**
- diffusion-weighted magnetic resonance imaging in boys with neural cell adhesion molecule L1 mutations and congenital hydrocephalus (Graf et al) 2000;47:113
 - intracellular adhesion molecule-1 polymorphisms and genetic susceptibility to multiple sclerosis: additional data and meta-analysis (Killestein et al) (Letter); (Luomala et al) (Reply) 2000;47:277
- Cell death**
- novel congenital myopathy with apoptotic changes (Ikezoe et al) 2000;47:531
 - novel Leu723Pro amyloid precursor protein mutation increases amyloid β 42(43) peptide levels and induces apoptosis (Kwok et al) 2000;47:249
 - partial deficiency of manganese superoxide dismutase exacerbates a transgenic mouse model of amyotrophic lateral sclerosis (Andreassen et al) 2000;47:447
- Cell line**
- IgG from "seronegative" myasthenia gravis patients binds to a muscle cell line, TE671, but not to human acetylcholine receptor (Blaes et al) 2000;47:504
- Cellular inclusions**
- inclusion body myositis, muscle blood vessel and cardiac amyloidosis, and transthyretin Val122Ile allele (Askanas et al) 2000;47:544
 - neuronal intranuclear inclusions in spinocerebellar atrophy type 2 (Koyano et al) 2000;47:550 (Letter)
- Central nervous system neoplasms**
- association of primary central nervous system lymphoma with long-term azathioprine therapy for myasthenia gravis? (Herrlinger et al) 2000;47:682 (Letter)
 - cerebrospinal fluid interleukin-10 levels in primary central nervous system lymphoma: a possible marker of response to treatment? (Salmaggi et al) 2000;47:137 (Letter)
- Centr^e median-parafascicular complex; see Thalamic nuclei**
- Cerebellar diseases**
- cytotoxic T cells in paraneoplastic cerebellar degeneration (Greenlee) 2000;47:4 (Editorial)
 - detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration (Alberti et al) 2000;47:9
- Cerebral atrophy; see Atrophy**
- Cerebral blood flow; see Brain, blood supply**
- Cerebral cortex**
- corticobasal degeneration shares a common genetic background with progressive supranuclear palsy (Di Maria et al) 2000;47:374
 - proinflammatory cytokines and interleukin-9 exacerbate excitotoxic lesions of the newborn murine neopallium (Dommergues et al) 2000;47:54
- Cerebral hemorrhage**
- hemorrhagic complications in vein of Galen malformations (Meyers et al) 2000;47:748
- Cerebral infarction**
- mice overexpressing rat heat shock protein 70 are protected against cerebral infarction (Rajdev et al) 2000; 47:782
- Cerebral ischemia**
- mice overexpressing rat heat shock protein 70 are protected against cerebral infarction (Rajdev et al) 2000; 47:782
 - penumbral tissue alkalosis in focal cerebral ischemia: relationship to energy metabolism, blood flow, and steady potential (Back et al) 2000;47:485
 - thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging (Kidwell et al) 2000;47:462
- Cerebral palsy**
- motor benefit from levodopa in spastic quadriplegic cerebral palsy (Brunstrom et al) 2000;47:662
- Cerebral veins**
- hemorrhagic complications in vein of Galen malformations (Meyers et al) 2000;47:748

Cerebrospinal fluid

- cerebrospinal fluid interleukin-10 levels in primary central nervous system lymphoma: a possible marker of response to treatment? (Salmaggi et al) 2000;47:137 (Letter)
cross-reactive idiotype in cerebrospinal fluid immunoglobulins in multiple sclerosis (LaGanke et al) 2000; 47:87
cytotoxic T cells in paraneoplastic cerebellar degeneration (Greenlee) 2000;47:4 (Editorial)
decreased cerebrospinal fluid levels of β -phenylethylamine in patients with Rett syndrome (Saito et al) 2000;47: 801
detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration (Albert et al) 2000;47:9
molecular analysis of the CDR3 encoding region of the immunoglobulin heavy chain locus in cerebrospinal fluid cells as a diagnostic tool in lymphomatous meningitis (Storch-Hagenlocher et al) 2000;47:211
nitration of manganese superoxide dismutase in cerebrospinal fluids is a marker for peroxynitrite-mediated oxidative stress in neurodegenerative disease (Aoyama et al) 2000;47:524
rapid clearance of human immunodeficiency virus (HIV-1) from ventricular cerebrospinal fluid (CSF) during antiretroviral treatment (Eggers et al) 2000;47: 816

Cerebrospinal fluid proteins

- 14-3-3 cerebrospinal fluid protein and Creutzfeldt-Jakob disease (Zeidler) (Letter); (Saiz et al) (Reply) 2000;47: 683
Cerebrovascular disorders
apoE facilitates neuritic and cerebrovascular plaque formation in the APPsw mouse model of Alzheimer's disease (Holtzman et al) 2000;47:739
de novo mutation in the *Notch3* gene causing CADASIL (Joutel et al) 2000;47:388
impaired reading in patients with right hemianopia (Leff et al) 2000;47:171
new magnetic resonance imaging methods for cerebrovascular disease: emerging clinical applications (Neumann-Haefelin et al) 2000;47:559 (Neurological progress)
oxidative phosphorylation defect in the brains of carriers of the tRNA^{Leu(CUR)} A3243G mutation in a MELAS pedigree (Dubeau et al) 2000;47:179
profile of endothelial and leukocyte activation in Fabry patients (DeGraba et al) 2000;47:229
recurrent strokes after varicella (Hattori et al) 2000;47:136 (Letter)
specific changes in somatosensory evoked magnetic fields during recovery from sensorimotor stroke (Wikström et al) 2000;47:353

Ceruloplasmin

- changes of copper transporting proteins and ceruloplasmin in the lentiform nuclei in primary adult-onset dystonia (Berg et al) 2000;47:827

Cervical dystonia; *see* Dystonia

- CFT PET; *see* Tomography, emission-computed
Charcot, Jean-Martin
William Osler: *On Chorea*: on Charcot (Goetz) 2000;47: 404 (History of neurology)

Charcot-Marie-Tooth disease

- hemizygous mutation of the peripheral myelin protein 22 gene associated with Charcot-Marie-Tooth disease type 1 (Numakura et al) 2000;47:101
recessive Charcot-Marie-Tooth disease (Lupski) 2000;47:6 (Editorial)

Chickenpox

- recurrent strokes after varicella (Hattori et al) 2000;47:136 (Letter)

Chlamydia pneumoniae

- Chlamydia, Rickettsia*, and antibiotic treatment of multiple sclerosis (Hoption Cann et al) (Letter); (Sriram et al) (Reply) 2000;47:408
evidence for infection with *Chlamydia pneumoniae* in a subgroup of patients with multiple sclerosis (Lay-Schmitt et al) 2000;47:652
multiple sclerosis and *Chlamydia pneumoniae* (Treib et al) 2000;47:408 (Letter)

Chorioretinitis

- congenital encephalomyopathy with epilepsy, chorioretinitis, basal ganglia involvement, and muscle minicores (Avoni et al) 2000;47:395

Chromosome deletion

- dopa-responsive dystonia due to a large deletion in the GTP cyclohydrolase I gene (Furukawa et al) 2000;47: 517

Chromosome mapping

- X-linked vacuolar myopathies: two separate loci and refined genetic mapping (Auranen et al) 2000;47:666

Chronic inflammatory demyelinating polyneuropathy; *see* Demyelinating polyneuropathy, chronic inflammatory

Chylomicrons

- vitamin E deficiency due to chylomicron retention disease in Marinesco-Sjögren syndrome (Aguiglia et al) 2000; 47:260

Citrulline

- three novel mutations (G27E, insAAC, R179X) in the *ORNT1* gene of Japanese patients with hyperornithinemia, hyperammonemia, and homocitrullinuria syndrome (Tsujino et al) 2000;47:624

Codons

- no association between the NOS3 codon 298 polymorphism and Alzheimer's disease in a sample from the United States (Crawford et al) 2000;47:687 (Letter)

Cognition disorders

- cerebral white matter lesions and cognitive function: the Rotterdam Scan Study (de Groot et al) 2000;47:145

Color

- Pocket Monsters* episode (Harding) (Letter); (Tobimatsu et al) (Reply) 2000;47:275

Congenital muscular dystrophy; *see* Muscular dystrophy

Convulsions

- neonatal seizures induced persistent changes in intrinsic properties of CA1 rat hippocampal cells (Villeneuve et al) 2000;47:729

- novel mutation of *KCNQ3* (c.925TC) in a Japanese family with benign familial neonatal convulsions (BFNC2) (Hirose et al) 2000;47:822

Convulsions, febrile

- clinical heterogeneity in pedigrees with 2q-linked febrile seizures (Moulard et al) 2000;47:840 (Letter)

- hippocampal sclerosis whodunit: enter the genes (Berkovic and Jackson) 2000;47:557 (Editorial)

- locus for febrile seizures (Scheffer et al) 2000;47:840 (Letter)

- prolonged febrile seizures in the immature rat model enhance hippocampal excitability long term (Dube et al) 2000;47:336

- Copaxone; see Glatiramer acetate**
- Copolymer-1; see Glatiramer acetate**
- Copper**
changes of copper transporting proteins and ceruloplasmin in the lentiform nuclei in primary adult-onset dystonia (Berg et al) 2000;47:827
- Corpus callosum**
quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis (Evangelou et al) 2000;47:391
- Corpus striatum**
levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease (Di Rocco and Werner) (Letter); (Muriel et al) (Reply) 2000;47:136
levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? (Calabresi et al) 2000;47:S60
nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment (Hirsch) 2000;47:S115
striatal mechanisms and pathogenesis of parkinsonian signs and motor complications (Chase and Oh) 2000; 47:S122
- Corrections**
congenital muscular dystrophy: an expanding clinical syndrome (Dubowitz) (2000;47:143) 2000;47:554
the mitochondrial DNA G13513A transition in ND5 is associated with LHON/MELAS overlap syndrome and may be a frequent cause of MELAS (Pulkes et al) (1999;46:916) 2000;47:841
- Cortical synchronization**
movement-related electroencephalographic desynchronization in patients with hand cramps: evidence for motor cortical involvement in focal dystonia (Toro et al) 2000;47:456
- COX; see Cytochrome c oxidase**
- CP-122,288**
no acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials (Roon et al) 2000;47:238
- Cramp; see Muscle cramp**
- Creatine**
mental retardation and behavioral problems as presenting signs of a creatine synthesis defect (van der Knaap et al) 2000;47:540
reversible brain creatine deficiency in two sisters with normal blood creatine level (Bianchi et al) 2000;47:511
- Creutzfeldt-Jakob disease**
14-3-3 cerebrospinal fluid protein and Creutzfeldt-Jakob disease (Zeidler) (Letter); (Saiz et al) (Reply) 2000;47: 683
Creutzfeldt-Jakob disease profile in patients homozygous for the PRNP E200K mutation (Simon et al) 2000;47: 257
diagnosis of new variant Creutzfeldt-Jakob disease (Will et al) 2000;47:575
- Cross reactions**
cross-reactive idiotype in cerebrospinal fluid immunoglobulins in multiple sclerosis (LaGanke et al) 2000; 47:87
- Cytochrome c oxidase**
differential features of patients with mutations in two COX assembly genes, *SURF-1* and *SCO2* (Sue et al) 2000;47:589
- Cytokines**
proinflammatory cytokines and interleukin-9 exacerbate excitotoxic lesions of the newborn murine neocortex (Dommergues et al) 2000;47:54
- Cytomegaloviruses**
no cytomegalovirus DNA in sera from patients with anti-MAG/SGPG antibody-associated neuropathy (Irie et al) (Letter); (Yamamoto and Yuki) (Reply) 2000;47:274
- Cytoplasm**
levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease (Di Rocco and Werner) (Letter); (Muriel et al) (Reply) 2000;47:136
- Deletion; see Chromosome deletion**
- Dementia**
age-related white matter changes and cognitive impairment (Inzitari) 2000;47:141 (Editorial)
"missing" tau mutation identified (Hutton) 2000;47:417 (Editorial)
mutations in the neuroserpin gene are rare in familial dementia (French Alzheimer's Disease Study Group and Fronto-Temporal Dementia Genetics Study Group) 2000;47:688 (Letter)
a novel mutation at position +12 in the intron following exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto) (Yasuda et al) 2000;47:422 voxel-based morphometry study of semantic dementia: relationship between temporal lobe atrophy and semantic memory (Mummery et al) 2000;47:36
- Demyelinating diseases**
acute inflammatory demyelination in reperfusion nerve injury (Nukada et al) 2000;47:71
heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination (Lucchinetti et al) 2000;47:707
- Demyelinating polyneuropathy, chronic inflammatory**
passive transfer of demyelination by serum of IgG from CIDP patients (Yan et al) 2000;47:765
- Depression**
major depression is a risk factor for seizures in older adults (Hesdorffer et al) 2000;47:246
- Dichlorphenamide**
randomized trials of dichlorphenamide in the periodic paroxysms (Tawil et al) 2000;47:46
- Diffusion magnetic resonance imaging; see Magnetic resonance imaging**
- DNA, mitochondrial**
MNGIE: an autosomal recessive disorder due to thymidine phosphorylase mutations (Nishino et al) 2000;47: 792
very low levels of the mtDNA A3243G mutation associated with mitochondrial dysfunction in vivo (Chinnery et al) 2000;47:381
- Dopamine**
clinical pharmacology of levodopa-induced dyskinesia (Nutt) 2000;47:S160
clinical physiology of dopa dyskinesia (Hallett) 2000;47: S147
dopamine receptors and locomotor responses: molecular aspects (Sealfon) 2000;47:S12

- dopamine-mediated gene regulation in models of Parkinson's disease (Gerfen) 2000;47:S42
- dopa-responsive dystonia due to a large deletion in the GTP cyclohydrolase I gene (Furukawa et al) 2000;47:517
- dyskinésias and the subthalamic nucleus (Benabid et al) 2000;47:S189
- factors influencing the onset and persistence of dyskinésias in MPTP-treated primates (Jenner) 2000;47:S90
- in vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease (Lee et al) 2000;47:493
- investigating levodopa-induced dyskinésias in the parkinsonian primate (Langston et al) 2000;47:S79
- levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease (Di Rocca and Werner) (Letter); (Muriel et al) (Reply) 2000;47:136
- levodopa-induced dyskinésias: a pathological form of striatal synaptic plasticity? (Calabresi et al) 2000;47:S60
- levodopa-induced dyskinésias: foreword (Olanow et al) 2000;47:S1
- levodopa-induced dyskinésias in Parkinson's disease: is sensitization reversible? (Bejjani et al) 2000;47:655
- medical treatment of levodopa-induced dyskinésias (Rascol) 2000;47:S179
- molecular basis of levodopa-induced dyskinésias (Calon et al) 2000;47:S70
- neural mechanisms underlying levodopa-induced dyskinésia in Parkinson's disease (Brotchie) 2000;47:S105
- neuroimaging of dyskinésias (Brooks et al) 2000;47:S154
- neuronal recordings in Parkinson's disease patients with dyskinésias induced by apomorphine (Lozano et al) 2000;47:S141
- nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment (Hirsch) 2000;47:S115
- pathophysiology of levodopa-induced dyskinésias in Parkinson's disease: problems with the current model (Obeso et al) 2000;47:S22
- patterns of gene expression and behavior induced by chronic dopamine treatments (Canales and Graybiel) 2000;47:S53
- physiologic basis of dyskinésias (Filion) 2000;47:S35
- physiology of hypokinetic and hyperkinetic movement disorders: model for dyskinésias (Vitek and Giroux) 2000;47:S131
- preventing levodopa-induced dyskinésias (Olanow and Obeso) 2000;47:S167
- progression in Parkinson's disease: a PET study with a dopamine transporter ligand [¹⁸F]CFT (Nurmi et al) 2000;47:804
- single nucleotide polymorphism of dopamine transporter gene is associated with Parkinson's disease (Morino et al) 2000;47:528
- spectrum of levodopa-induced dyskinésias (Fahn) 2000;47:S2
- striatal mechanisms and pathogenesis of parkinsonian signs and motor complications (Chase and Oh) 2000;47:S122
- surgery for levodopa-induced dyskinésias (Lang) 2000;47:S193
- α -synuclein and Parkinson's disease: selective neurodegenerative effect of α -synuclein fragment on dopaminergic neurons in vitro and in vivo (Forloni et al) 2000;47:632
- Doublecortin**
genetic and neuroradiological heterogeneity of double cortex syndrome (Gleeson et al) 2000;47:265
- Dystonia, drug-induced**
clinical pharmacology of levodopa-induced dyskinésias (Nutt) 2000;47:S160
- clinical physiology of dopa dyskinésias (Hallett) 2000;47:S147
- dopamine receptors and locomotor responses: molecular aspects (Sealfon) 2000;47:S12
- dopamine-mediated gene regulation in models of Parkinson's disease (Gerfen) 2000;47:S42
- dyskinésias and the subthalamic nucleus (Benabid et al) 2000;47:S189
- factors influencing the onset and persistence of dyskinésias in MPTP-treated primates (Jenner) 2000;47:S90
- investigating levodopa-induced dyskinésias in the parkinsonian primate (Langston et al) 2000;47:S79
- levodopa-induced dyskinésias: a pathological form of striatal synaptic plasticity? (Calabresi et al) 2000;47:S60
- levodopa-induced dyskinésias: foreword (Olanow et al) 2000;47:S1
- levodopa-induced dyskinésias in Parkinson's disease: is sensitization reversible? (Bejjani et al) 2000;47:655
- medical treatment of levodopa-induced dyskinésias (Rascol) 2000;47:S179
- molecular basis of levodopa-induced dyskinésias (Calon et al) 2000;47:S70
- neural mechanisms underlying levodopa-induced dyskinésia in Parkinson's disease (Brotchie) 2000;47:S105
- neuroimaging of dyskinésias (Brooks et al) 2000;47:S154
- neuronal recordings in Parkinson's disease patients with dyskinésias induced by apomorphine (Lozano et al) 2000;47:S141
- nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment (Hirsch) 2000;47:S115
- pathophysiology of levodopa-induced dyskinésias in Parkinson's disease: problems with the current model (Obeso et al) 2000;47:S22
- patterns of gene expression and behavior induced by chronic dopamine treatments (Canales and Graybiel) 2000;47:S53
- physiologic basis of dyskinésias (Filion) 2000;47:S35
- physiology of hypokinetic and hyperkinetic movement disorders: model for dyskinésias (Vitek and Giroux) 2000;47:S131
- preventing levodopa-induced dyskinésias (Olanow and Obeso) 2000;47:S167
- spectrum of levodopa-induced dyskinésias (Fahn) 2000;47:S2
- striatal mechanisms and pathogenesis of parkinsonian signs and motor complications (Chase and Oh) 2000;47:S122
- surgery for levodopa-induced dyskinésias (Lang) 2000;47:S193
- Dyslexia, acquired**
impaired reading in patients with right hemianopia (Leff et al) 2000;47:171
- Dystonia**
changes of copper transporting proteins and ceruloplasmin in the lentiform nuclei in primary adult-onset dystonia (Berg et al) 2000;47:827
- dopa-responsive dystonia due to a large deletion in the GTP cyclohydrolase I gene (Furukawa et al) 2000;47:517

movement-related electroencephalographic desynchronization in patients with hand cramps: evidence for motor cortical involvement in focal dystonia (Toro et al) 2000;47:456

sensory discrimination capabilities in patients with focal hand dystonia (Bara-Jimenez et al) 2000;47:377

sensory tricks in cervical dystonia: perceptual dysbalance of parietal cortex modulates frontal motor programming (Naumann et al) 2000;47:322

Elastase

serum elastase activity is elevated in migraine (Tzourio et al) 2000;47:648

Elderly; *see* Aged

Electric stimulation

intraoperative unmasking of brain redundant motor sites during resection of a precentral angioma: evidence using direct cortical stimulation (Duffau et al) 2000;47:132

Electroencephalography

movement-related electroencephalographic desynchronization in patients with hand cramps: evidence for motor cortical involvement in focal dystonia (Toro et al) 2000;47:456

Encephalitis

age-related white matter changes and cognitive impairment (Inzitari) 2000;47:141 (Editorial)

Encephalomyelitis

combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN- α) does not improve experimental autoimmune encephalomyelitis (Brod et al) 2000;47:127

Endothelins

endothelin inhibition improves cerebral blood flow and is neuroprotective in pneumococcal meningitis (Pfister et al) 2000;47:329

endothelin-1 in the brain of patients with galactosialidosis: its abnormal increase and distribution pattern (Itoh et al) 2000;47:122

Endothelium

in vitro glatiramer acetate treatment of brain endothelium does not reduce adhesion phenomena (Dufour et al) (Letter); (Dufour et al) (Reply) 2000;47:680

no association between the NOS3 codon 298 polymorphism and Alzheimer's disease in a sample from the United States (Crawford et al) 2000;47:687 (Letter)

profile of endothelial and leukocyte activation in Fabry patients (DeGraba et al) 2000;47:229

Energy metabolism

higher sedentary energy expenditure in patients with Huntington's disease (Pratley et al) 2000;47:64

penumbral tissue alkalosis in focal cerebral ischemia: relationship to energy metabolism, blood flow, and steady potential (Back et al) 2000;47:485

reversible brain creatine deficiency in two sisters with normal blood creatine level (Bianchi et al) 2000;47:511

Epilepsy

congenital encephalomyopathy with epilepsy, chorioretinitis, basal ganglia involvement, and muscle minicores (Avoni et al) 2000;47:395

genetic and neuroradiological heterogeneity of double cortex syndrome (Gleeson et al) 2000;47:265

increased bone turnover in epileptic patients treated with carbamazepine (Verratti et al) 2000;47:385

major depression is a risk factor for seizures in older adults (Hesdorffer et al) 2000;47:246

nonsense mutation of the *ATRX* gene causing mild mental retardation and epilepsy (Guerrini et al) 2000;47:117 valproate for girls with epilepsy (Balen and Genton) (Letter); (Isojärvi et al) (Reply) 2000;47:550

Epilepsy, temporal lobe

hippocampal sclerosis whodunit: enter the genes (Berkovic and Jackson) 2000;47:557 (Editorial)

interleukin (IL)-1 β , IL-1 α , and IL-1 receptor antagonist gene polymorphisms in patients with temporal lobe epilepsy (Kanemoto et al) 2000;47:571

prognostic value of proton magnetic resonance spectroscopic imaging for surgical outcome in patients with intractable temporal lobe epilepsy and bilateral hippocampal atrophy (Li et al) 2000;47:195

prolonged febrile seizures in the immature rat model enhance hippocampal excitability long term (Dube et al) 2000;47:36

Episodic ataxia; *see* Ataxia

Essential tremor; *see* Tremor

Evoked potentials, somatosensory

specific changes in somatosensory evoked magnetic fields during recovery from sensorimotor stroke (Wikström et al) 2000;47:353

Excitotoxins; *see* Neurotoxins

Exons

"missing" tau mutation identified (Hutton) 2000;47:417 (Editorial)

a novel mutation at position +12 in the intron following exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto) (Yasuda et al) 2000;47:422

Experimental autoimmune encephalomyelitis; *see* Encephalomyelitis

Eye movements

common mechanism for the control of eye and head movements in humans (Gaymard et al) 2000;47:819

Fabry's disease

profile of endothelial and leukocyte activation in Fabry patients (DeGraba et al) 2000;47:229

Familial frontotemporal dementia; *see* Dementia

Fatty acids

simvastatin and plasma very-long-chain fatty acids in X-linked adrenoleukodystrophy (Verrips et al) 2000;47:552 (Letter)

Febrile seizures; *see* Convulsions, febrile

Flumazenil

benzodiazepine receptor binding in Huntington's disease: [11 C]flumazenil uptake measured using positron emission tomography (Künig et al) 2000;47:644

Fluorescent antibody technique

rapid diagnosis of peroxisome biogenesis disorders by means of immunofluorescence staining of buccal smears (Zhang et al) 2000;47:836 (Letter)

Focal cerebral ischemia; *see* Cerebral ischemia

Focal dystonia; *see* Dystonia

Forgetfulness; *see* Memory disorders

Free radicals

mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse (Tabrizi et al) 2000;47:80

Friedreich's ataxia

increased serum transferrin receptor concentrations in Friedreich ataxia (Wilson et al) 2000;47:659

Frontal lobe

sensory tricks in cervical dystonia: perceptual dysbalance of parietal cortex modulates frontal motor programming (Naumann et al) 2000;47:322

Fukutin protein

fukutin protein is expressed in neurons of the normal developing human brain but is reduced in Fukuyama-type congenital muscular dystrophy brain (Saito et al) 2000; 47:756

Fukuyama muscular dystrophy; see Muscular dystrophy**Fumarate hydratase**

fumaric aciduria: clinical and imaging features (Kerrigan et al) 2000;47:583

Functional magnetic resonance imaging; see Magnetic resonance imaging**Gadolinium**

seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis (Auer et al) 2000;47:276 (Letter)

Galactosialidosis

endothelin-1 in the brain of patients with galactosialidosis: its abnormal increase and distribution pattern (Itoh et al) 2000;47:122

Ganglia, spinal

clinical and magnetic resonance imaging findings in chronic sensory ganglionopathies (Lauria et al) 2000; 47:104

Gangliosides

circulating antiganglioside antibodies are not associated with the development of progressive disease or cerebral atrophy in patients with multiple sclerosis (Giovannoni et al) (Letter); (Sadatipour et al) (Reply) 2000;47:684

Gene expression

patterns of gene expression and behavior induced by chronic dopamine treatments (Canales and Graybiel) 2000;47:S53

Gene mutation; see Mutation**Gene products, Tat**

synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine (Nath et al) 2000;47:186

Gene regulation

dopamine-mediated gene regulation in models of Parkinson's disease (Gerfen) 2000;47:S42

Genes

hippocampal sclerosis whodunit: enter the genes (Berkovic and Jackson) 2000;47:557 (Editorial)

Genes, immunoglobulin

molecular analysis of the CDR3 encoding region of the immunoglobulin heavy chain locus in cerebrospinal fluid cells as a diagnostic tool in lymphomatous meningitis (Storch-Hagenlocher et al) 2000;47:211

Genetic mapping; see Chromosome mapping**Genotype**

significant association between the tau gene A0/A0 genotype and Parkinson's disease (Pastor et al) 2000;47:242

Glatiramer acetate

combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN- α) does not improve experimental autoimmune encephalomyelitis (Brod et al) 2000;47:127

effect of glatiramer acetate (Copaxone) given orally in human patients: interleukin-10 production during a Phase 1 trial (de Seze et al) 2000;47:686 (Letter)

in vitro glatiramer acetate treatment of brain endothelium does not reduce adhesion phenomena (Dufour et al) (Letter); (Dufour et al) (Reply) 2000;47:680

1,4- α -Glucan branching enzyme

novel missense mutations in the glycogen-branching enzyme gene in adult polyglucosan body disease (Ziemssen et al) 2000;47:536

Glutamates

glutamate uptake is decreased in platelets from Alzheimer's disease patients (Ferrarese et al) 2000;47:641

up-regulation of the metabotropic glutamate receptor mGluR4 in hippocampal neurons with reduced seizure vulnerability (Lie et al) 2000;47:26

Glycans; see Polysaccharides**Glycogen**

novel missense mutations in the glycogen-branching enzyme gene in adult polyglucosan body disease (Ziemssen et al) 2000;47:536

Glycoproteins

endothelin-1 in the brain of patients with galactosialidosis: its abnormal increase and distribution pattern (Itoh et al) 2000;47:122

no cytomegalovirus DNA in sera from patients with anti-MAG/SGPG antibody-associated neuropathy (Irie et al) (Letter); (Yamamoto and Yuki) (Reply) 2000;47:274

Glycosylation

clinical and biochemical characteristics of congenital disorder of glycosylation: CDG-Ic, the first recognized ER defect in N-glycan synthesis (Grönwald et al) 2000; 47:776

G(M1) ganglioside

clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside (Yuki et al) 2000;47:314

gp120(HIV); see HIV envelope protein gp120**GTP cyclohydrolase**

dopa-responsive dystonia due to a large deletion in the GTP cyclohydrolase I gene (Furukawa et al) 2000;47: 517

Guillain-Barré syndrome; see Polyradiculoneuritis**Hand**

movement-related electroencephalographic desynchronization in patients with hand cramps: evidence for motor cortical involvement in focal dystonia (Toro et al) 2000;47:456

sensory discrimination capabilities in patients with focal hand dystonia (Bara-Jimenez et al) 2000;47:377

Head movements

common mechanism for the control of eye and head movements in humans (Gaymard et al) 2000;47:819

Headache

association between migraine and cutaneous allodynia (Burstein et al) 2000;47:614

de novo mutation in the Notch3 gene causing CADASIL (Joutel et al) 2000;47:388

magnetic resonance spectroscopy of episodic ataxia type 2 and migraine (Montagna et al) (Letter); (Sappéy-Marinier et al) (Reply) 2000;47:838

no acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials (Roon et al) 2000;47:238

serum elastase activity is elevated in migraine (Tzourio et al) 2000;47:648

Heat shock proteins

mice overexpressing rat heat shock protein 70 are protected against cerebral infarction (Rajdev et al) 2000; 47:782

Hemangioma

intraoperative unmasking of brain redundant motor sites during resection of a precentral angioma: evidence using direct cortical stimulation (Duffau et al) 2000; 47: 132

Spanish families with cerebral cavernous angioma do not bear 742C[rightarrow]T Hispanic-American mutation of the KRIT1 gene (Lucas et al) 2000; 47:836 (Letter)

Hematocrit

subtle brain abnormalities in children with sickle cell disease: relationship to blood hematocrit (Rivera) (Letter); (Steen et al) (Reply) 2000; 47:279

Hemianopsia

impaired reading in patients with right hemianopsia (Leff et al) 2000; 47:171

Herpesvirus hominis

increased lymphoproliferative response to human herpesvirus type 6A variant in multiple sclerosis patients (Sodan et al) 2000; 47:306

Hippocampal sclerosis

hippocampal sclerosis whodunit: enter the genes (Berkovic and Jackson) 2000; 47:557 (Editorial)

interleukin (IL)-1 β , IL-1 α , and IL-1 receptor antagonist gene polymorphisms in patients with temporal lobe epilepsy (Kanemoto et al) 2000; 47:571

Hippocampus

neonatal seizures induced persistent changes in intrinsic properties of CA1 rat hippocampal cells (Villeneuve et al) 2000; 47:729

prognostic value of proton magnetic resonance spectroscopic imaging for surgical outcome in patients with intractable temporal lobe epilepsy and bilateral hippocampal atrophy (Li et al) 2000; 47:195

prolonged febrile seizures in the immature rat model enhance hippocampal excitability long term (Dube et al) 2000; 47:336

up-regulation of the metabotropic glutamate receptor mGluR4 in hippocampal neurons with reduced seizure vulnerability (Lie et al) 2000; 47:26

Historical article

William Osler: *On Chorea*: on Charcot (Goetz) 2000; 47: 404 (History of neurology)

HIV envelope protein gp120

synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine (Nath et al) 2000; 47:186

HIV-1

rapid clearance of human immunodeficiency virus (HIV-1) from ventricular cerebrospinal fluid (CSF) during antiretroviral treatment (Eggers et al) 2000; 47: 816

synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine (Nath et al) 2000; 47:186

HLA antigens

contribution of HLA to multiple sclerosis susceptibility in Sardinian affected sibling pairs (Marrosu et al) 2000; 47: 411 (Letter)

Holoprosencephaly

sonic hedgehog signal peptide mutation in a patient with holoprosencephaly (Kato et al) 2000; 47:514

Homocitrullinuria; see Citrulline

Human immunodeficiency virus-1; see HIV-1

Huntington chorea

benzodiazepine receptor binding in Huntington's disease: [11 C]flumazenil uptake measured using positron emission tomography (Künig et al) 2000; 47:644

higher sedentary energy expenditure in patients with Huntington's disease (Pratley et al) 2000; 47:64

mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse (Tabrizi et al) 2000; 47:80

Hydrocephalus

diffusion-weighted magnetic resonance imaging in boys with neural cell adhesion molecule L1 mutations and congenital hydrocephalus (Graf et al) 2000; 47:113

Hyperammonemia; see Ammonia

Hyperkinesia

physiology of hypokinetic and hyperkinetic movement disorders: model for dyskinesia (Vitek and Giroux) 2000; 47:S131

Hyperornithinemia; see Ornithine

Hypokinesia

physiology of hypokinetic and hyperkinetic movement disorders: model for dyskinesia (Vitek and Giroux) 2000; 47:S131

IgA

myelin widenings and MGUS-IgA: an immunoelectron based microscopic study (Vallat et al) 2000; 47:808

IgG

IgG from "seronegative" myasthenia gravis patients binds to a muscle cell line, TE671, but not to human acetylcholine receptor (Blaes et al) 2000; 47:504

passive transfer of demyelination by serum of IgG from CIDP patients (Yan et al) 2000; 47:765

Immunoelectron microscopy; see Microscopy, electron

Immunofluorescence technique; see Fluorescent antibody technique

Immunoglobulin heavy chain locus; see Genes, immunoglobulin

Immunoglobulin idiotypes

cross-reactive idiotype in cerebrospinal fluid immunoglobulins in multiple sclerosis (LaGanke et al) 2000; 47:87

Inborn errors of metabolism; see Metabolism, inborn errors

Inclusion bodies; see Cellular inclusions

partial laminin α 2 chain deficiency in a patient with myopathy resembling inclusion body myositis (Di Blasi et al) 2000; 47:811

Infant, newborn

neonatal seizures induced persistent changes in intrinsic properties of CA1 rat hippocampal cells (Villeneuve et al) 2000; 47:729

novel mutation of KCNQ3 (c.925TC) in a Japanese family with benign familial neonatal convulsions (BFNC2) (Hirose et al) 2000; 47:822

proinflammatory cytokines and interleukin-9 exacerbate excitotoxic lesions of the newborn murine neopallium (Dommergues et al) 2000; 47:54

Infection

Chlamydia, Rickettsia, and antibiotic treatment of multiple sclerosis (Hoption Cann et al) (Letter); (Sriram et al) (Reply) 2000; 47:408

evidence for infection with *Chlamydia pneumoniae* in a subgroup of patients with multiple sclerosis (Layh-Schmitt et al) 2000; 47:652

Inflammation

acute inflammatory demyelination in reperfusion nerve injury (Nukada et al) 2000;47:71

Intelligence tests

subtle brain abnormalities in children with sickle cell disease: relationship to blood hematocrit (Rivera) (Letter); (Steen et al) (Reply) 2000;47:279

Interferon type I

combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN- α) does not improve experimental autoimmune encephalomyelitis (Brod et al) 2000;47:127

Interferon-gamma

increased numbers of CCR5 $^+$ interferon- γ and tumor necrosis factor- α -secreting T lymphocytes in multiple sclerosis patients (Strunk et al) 2000;47:269

Interleukin-1

Alzheimer's disease risk and the interleukin-1 genes (Tanzi) 2000;47:283 (Editorial)

association of early-onset Alzheimer's disease with an interleukin-1 α gene polymorphism (Grimaldi et al) 2000;47:361

association of interleukin-1 gene polymorphisms with Alzheimer's disease (Nicoll et al) 2000;47:365

interleukin (IL)-1 β , IL-1 α , and IL-1 receptor antagonist gene polymorphisms in patients with temporal lobe epilepsy (Kanemoto et al) 2000;47:571

Interleukin-6

gene-gene interaction between interleukin-6 and α_2 -macroglobulin influences the risk for Alzheimer's disease (Baglì et al) 2000;47:138 (Letter)

Interleukin-9

proinflammatory cytokines and interleukin-9 exacerbate excitotoxic lesions of the newborn murine neopallium (Dommergues et al) 2000;47:54

Interleukin-10

cerebrospinal fluid interleukin-10 levels in primary central nervous system lymphoma: a possible marker of response to treatment? (Salmaggi et al) 2000;47:137 (Letter)

effect of glatiramer acetate (Copaxone) given orally in human patients: interleukin-10 production during a Phase 1 trial (de Seze et al) 2000;47:686 (Letter)

Intracellular adhesion molecules; see Cell adhesion molecules

Introns

"missing" tau mutation identified (Hutton) 2000;47:417 (Editorial)

a novel mutation at position +12 in the intron following exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto) (Yasuda et al) 2000;47:422

Japan

novel mutation of KCNQ3 (c.925TC) in a Japanese family with benign familial neonatal convulsions (BFNC2) (Hirose et al) 2000;47:822

three novel mutations (G27E, insAAC, R179X) in the ORNT1 gene of Japanese patients with hyperornithinemia, hyperammonemia, and homocitrullinuria syndrome (Tsujino et al) 2000;47:624

Journal

message from the editor (Johnson) 2000;47:1 (Editorial)

Laminin

partial laminin α 2 chain deficiency in a patient with my-

opathy resembling inclusion body myositis (Di Blasi et al) 2000;47:811

Language

verbal fluency activates the left medial temporal lobe: a functional magnetic resonance imaging study (Pihlajamäki et al) 2000;47:470

Leukocytes

profile of endothelial and leukocyte activation in Fabry patients (DeGraba et al) 2000;47:229

Levodopa

clinical pharmacology of levodopa-induced dyskinesia (Nutt) 2000;47:S160

clinical physiology of dopa dyskinesia (Hallett) 2000;47:S147

dopamine receptors and locomotor responses: molecular aspects (Sealfon) 2000;47:S12

dopamine-mediated gene regulation in models of Parkinson's disease (Gerfen) 2000;47:S42

dyskinesias and the subthalamic nucleus (Benabid et al) 2000;47:S189

factors influencing the onset and persistence of dyskinesia in MPTP-treated primates (Jenner) 2000;47:S90

investigating levodopa-induced dyskinesias in the parkinsonian primate (Langston et al) 2000;47:S79

levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease (Di Rocco and Werner) (Letter); (Muriel et al) (Reply) 2000;47:136

levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? (Calabresi et al) 2000;47:S60

levodopa-induced dyskinesias: foreword (Olanow et al) 2000;47:S1

levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible? (Bejjani et al) 2000;47:655

medical treatment of levodopa-induced dyskinesias (Rascol) 2000;47:S179

molecular basis of levodopa-induced dyskinesias (Calon et al) 2000;47:S70

motor benefit from levodopa in spastic quadriplegic cerebral palsy (Brunstrom et al) 2000;47:662

neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease (Brotchie) 2000;47:S105

neuroimaging of dyskinesia (Brooks et al) 2000;47:S154

neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine (Lozano et al) 2000;47:S141

nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment (Hirsch) 2000;47:S115

pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model (Obeso et al) 2000;47:S22

patterns of gene expression and behavior induced by chronic dopamine treatments (Canales and Graybiel) 2000;47:S53

physiologic basis of dyskinesia (Filion) 2000;47:S35

physiology of hypokinetic and hyperkinetic movement disorders: model for dyskinesia (Vitek and Giroux) 2000;47:S131

preventing levodopa-induced dyskinesias (Olanow and Obeso) 2000;47:S167

spectrum of levodopa-induced dyskinesias (Fahn) 2000;47:S2

striatal mechanisms and pathogenesis of parkinsonian signs and motor complications (Chase and Oh) 2000;47:S122

surgery for levodopa-induced dyskinésias (Lang) 2000;47: S193

Lewy bodies

regional brain atrophy in progressive supranuclear palsy and Lewy body disease (Cordato et al) 2000;47:718 synphilin-1 is present in Lewy bodies in Parkinson's disease (Wakabayashi et al) 2000;47:521

Limbic system

prolonged febrile seizures in the immature rat model enhance hippocampal excitability long term (Dube et al) 2000;47:336

Lymphoma

association of primary central nervous system lymphoma with long-term azathioprine therapy for myasthenia gravis? (Herrlinger et al) 2000;47:682 (Letter) cerebrospinal fluid interleukin-10 levels in primary central nervous system lymphoma: a possible marker of response to treatment? (Salmaggi et al) 2000;47:137 (Letter)

Lymphoma, B-cell

molecular analysis of the CDR3 encoding region of the immunoglobulin heavy chain locus in cerebrospinal fluid cells as a diagnostic tool in lymphomatous meningitis (Storch-Hagenlocher et al) 2000;47:211

Lymphoproliferative disorders

increased lymphoproliferative response to human herpesvirus type 6A variant in multiple sclerosis patients (Soldan et al) 2000;47:306

Macroglobulins

gene-gene interaction between interleukin-6 and α_2 -macroglobulin influences the risk for Alzheimer's disease (Bagli et al) 2000;47:138 (Letter)

Magnetic resonance imaging

assessment of cerebral blood flow in Alzheimer's disease by spin-labeled magnetic resonance imaging (Alsop et al) 2000;47:93

clinical and magnetic resonance imaging findings in chronic sensory ganglionopathies (Lauria et al) 2000; 47:104

congenital encephalomyopathy with epilepsy, chorioretinitis, basal ganglia involvement, and muscle minicores (Avoni et al) 2000;47:395

diffusion-weighted magnetic resonance imaging in boys with neural cell adhesion molecule L1 mutations and congenital hydrocephalus (Graf et al) 2000;47:113

genetic and neuroradiological heterogeneity of double cortex syndrome (Gleeson et al) 2000;47:265

heterogeneity of T-lymphocyte function in primary progressive multiple sclerosis: relation to magnetic resonance imaging lesion volume (Prat et al) 2000;47:234

in vivo visualization of human neural pathways in magnetic resonance imaging (Mori et al) 2000;47:412 (Letter)

new magnetic resonance imaging methods for cerebrovascular disease: emerging clinical applications (Neumann-Haefelin et al) 2000;47:559 (Neurological progress)

seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis (Auer et al) 2000;47:276 (Letter)

thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging (Kidwell et al) 2000;47:462

use of structural magnetic resonance imaging to predict who will get Alzheimer's disease (Killiany et al) 2000; 47:430

verbal fluency activates the left medial temporal lobe: a functional magnetic resonance imaging study (Pihlajamäki et al) 2000;47:470

very low levels of the mtDNA A3243G mutation associated with mitochondrial dysfunction in vivo (Chinnery et al) 2000;47:381

Magnetic resonance spectroscopy; see Nuclear magnetic resonance

Magnetics

specific changes in somatosensory evoked magnetic fields during recovery from sensorimotor stroke (Wikström et al) 2000;47:353

Manganese

nitration of manganese superoxide dismutase in cerebrospinal fluids is a marker for peroxynitrite-mediated oxidative stress in neurodegenerative disease (Aoyama et al) 2000;47:524

partial deficiency of manganese superoxide dismutase exacerbates a transgenic mouse model of amyotrophic lateral sclerosis (Andreasen et al) 2000;47:447

Marinesco-Sjögren syndrome; see Spinocerebellar degeneration

MELAS syndrome

oxidative phosphorylation defect in the brains of carriers of the tRNA^{Leu(UUR)} A3243G mutation in a MELAS pedigree (Dubeau et al) 2000;47:179

Memantine

synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine (Nath et al) 2000;47:186

Memory disorders

cerebral white matter lesions and cognitive function: the Rotterdam Scan Study (de Groot et al) 2000;47:145 mere forgetfulness or early Alzheimer's disease? (Rossor and Fox) 2000;47:419 (Editorial)

voxel-based morphometry study of semantic dementia: relationship between temporal lobe atrophy and semantic memory (Mummery et al) 2000;47:36

Meninges

meningeal cells can communicate with astrocytes by calcium signaling (Grafstein et al) 2000;47:18

Meningitis

molecular analysis of the CDR3 encoding region of the immunoglobulin heavy chain locus in cerebrospinal fluid cells as a diagnostic tool in lymphomatous meningitis (Storch-Hagenlocher et al) 2000;47:211

Meningitis, pneumococcal

endothelin inhibition improves cerebral blood flow and is neuroprotective in pneumococcal meningitis (Pfister et al) 2000;47:329

Mental retardation

genetic and neuroradiological heterogeneity of double cortex syndrome (Gleeson et al) 2000;47:265

mental retardation and behavioral problems as presenting signs of a creatine synthesis defect (van der Knaap et al) 2000;47:540

nonsense mutation of the *ATRX* gene causing mild mental retardation and epilepsy (Guerrini et al) 2000;47:117

Metabolism, inborn errors

fumaric aciduria: clinical and imaging features (Kerrigan et al) 2000;47:583

Metabotropic glutamate receptor; see Glutamates

Methionine

diagnosis of new variant Creutzfeldt-Jakob disease (Will et al) 2000;47:575

- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine**
factors influencing the onset and persistence of dyskinesia
in MPTP-treated primates (Jenner) 2000;47:S90
- Microbodies**
peroxisome 1, 2, 3 ... (Rizzo) 2000;47:281 (Editorial)
pharmacological induction of peroxisomes in peroxisome
biogenesis disorders (Wei et al) 2000;47:286
rapid diagnosis of peroxisome biogenesis disorders by
means of immunofluorescence staining of buccal smears
(Zhang et al) 2000;47:836 (Letter)
- Microscopy, electron**
myelin widenings and MGUS-IgA: an immunolectron
based microscopic study (Vallat et al) 2000;47:808
- Migraine**
association between migraine and cutaneous allodynia
(Burstein et al) 2000;47:614
de novo mutation in the *Notch3* gene causing CADASIL
(Joutel et al) 2000;47:388
magnetic resonance spectroscopy of episodic ataxia type 2
and migraine (Montagna et al) (Letter); (Sappey-
Marinier et al) (Reply) 2000;47:838
no acute antimigraine efficacy of CP-122,288, a highly
potent inhibitor of neurogenic inflammation: results of
two randomized, double-blind, placebo-controlled clinical
trials (Roon et al) 2000;47:238
serum elastase activity is elevated in migraine (Tzourio et
al) 2000;47:648
- Mirror agnosia**
mirror agnosia: the Ramachandran sign (Altschuler) (Letter); (Binkofski et al) (Reply) 2000;47:553
- Missense mutation; see Mutation**
- Mitochondria**
mitochondrial dysfunction and free radical damage in the
Huntington R6/2 transgenic mouse (Tabrizi et al)
2000;47:80
- Mitochondrial neurogastrointestinal encephalomyopathy**
MNGIE: an autosomal recessive disorder due to thymidine
phosphorylase mutations (Nishino et al) 2000;47:
792
- Monoclonal gammopathies**
myelin widenings and MGUS-IgA: an immunolectron
based microscopic study (Vallat et al) 2000;47:808
- Motor cortex**
intraoperative unmasking of brain redundant motor sites
during resection of a precentral angioma: evidence using
direct cortical stimulation (Duffau et al) 2000;47:
132
motor cortex shows adaptive functional changes to brain
injury from multiple sclerosis (Lee et al) 2000;47:606
movement-related electroencephalographic desynchronization
in patients with hand cramps: evidence for motor
cortical involvement in focal dystonia (Toro et al)
2000;47:456
sensory tricks in cervical dystonia: perceptual dysbalance
of parietal cortex modulates frontal motor programming
(Naumann et al) 2000;47:322
- Motor neuron disease**
functional motor unit failure precedes neuromuscular degeneration
in canine motor neuron disease (Balice-Gordon et al) 2000;47:596
- Motor neurons**
partial deficiency of manganese superoxide dismutase exacerbates a transgenic mouse model of amyotrophic lateral sclerosis (Andreassen et al) 2000;47:447
- Movement disorders**
movement-related electroencephalographic desynchronization
in patients with hand cramps: evidence for motor
- cortical involvement in focal dystonia (Toro et al)
2000;47:456
physiology of hypokinetic and hyperkinetic movement disorders: model for dyskinesia (Vitek and Giroux)
2000;47:S131
- MPTP; see 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine**
- mRNA; see RNA, messenger**
- mtDNA; see DNA, mitochondrial**
- Multiple sclerosis, analysis**
cross-reactive idiotypic in cerebrospinal fluid immunoglobulins in multiple sclerosis (LaGanke et al) 2000;
47:87
- Multiple sclerosis, diagnosis**
diagnostic criteria for primary progressive multiple sclerosis: a position paper (Thompson et al) 2000;47:831
(Special report)
- Multiple sclerosis, drug therapy**
effect of glatiramer acetate (Copaxone) given orally in human patients: interleukin-10 production during a Phase 1 trial (de Seze et al) 2000;47:686 (Letter)
in vitro glatiramer acetate treatment of brain endothelium does not reduce adhesion phenomena (Dufour et al)
(Letter); (Dufour et al) (Reply) 2000;47:680
- Multiple sclerosis, etiology**
Chlamydia, Rickettsia, and antibiotic treatment of multiple sclerosis (Hopton Cann et al) (Letter); (Sriram et al)
(Reply) 2000;47:408
evidence for infection with *Chlamydia pneumoniae* in a subgroup of patients with multiple sclerosis (Layh-Schmitz et al) 2000;47:652
increased lymphoproliferative response to human herpesvirus type 6A variant in multiple sclerosis patients (Soland et al) 2000;47:306
multiple sclerosis and *Chlamydia pneumoniae* (Treib et al)
2000;47:408 (Letter)
understanding multiple sclerosis: lessons from pathology (Ludwin) 2000;47:691 (Editorial)
- Multiple sclerosis, genetics**
contribution of HLA to multiple sclerosis susceptibility in Sardinian affected sibling pairs (Marrosu et al) 2000;47:
411 (Letter)
intracellular adhesion molecule-1 polymorphisms and genetic susceptibility to multiple sclerosis: additional data and meta-analysis (Killestein et al) (Letter); (Luomala et al) (Reply) 2000;47:277
- Multiple sclerosis, pathology**
circulating antiganglioside antibodies are not associated with the development of progressive disease or cerebral atrophy in patients with multiple sclerosis (Giovannoni et al) (Letter); (Sadatipour et al) (Reply) 2000;47:684
heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination (Lucchinetti et al)
2000;47:707
heterogeneity of T-lymphocyte function in primary progressive multiple sclerosis: relation to magnetic resonance imaging lesion volume (Prat et al) 2000;47:234
increased numbers of CCR5⁺ interferon- γ and tumor necrosis factor- α -secreting T lymphocytes in multiple sclerosis patients (Strunk et al) 2000;47:269
motor cortex shows adaptive functional changes to brain injury from multiple sclerosis (Lee et al) 2000;47:606
quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis (Evangelou et al) 2000;47:391
role of B cells and autoantibodies in multiple sclerosis (Archelos et al) 2000;47:694 (Neurological progress)

seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis (Auer et al) 2000;47:276 (Letter)
understanding multiple sclerosis: lessons from pathology (Ludwin) 2000;47:691 (Editorial)

Muscle cramp

movement-related electroencephalographic desynchronization in patients with hand cramps: evidence for motor cortical involvement in focal dystonia (Toro et al) 2000;47:456

Muscular atrophy, spinal

functional motor unit failure precedes neuromuscular degeneration in canine motor neuron disease (Balice-Gordon et al) 2000;47:596

Muscular diseases

functional motor unit failure precedes neuromuscular degeneration in canine motor neuron disease (Balice-Gordon et al) 2000;47:596

novel congenital myopathy with apoptotic changes (Ikezoe et al) 2000;47:531

partial laminin $\alpha 2$ chain deficiency in a patient with myopathy resembling inclusion body myositis (Di Blasi et al) 2000;47:811

X-linked vacuolar myopathies: two separate loci and refined genetic mapping (Auranen et al) 2000;47:666

Muscular dystonia

congenital muscular dystrophy with rigid spine syndrome: a clinical, pathological, radiological, and genetic study (Flanigan et al) 2000;47:152

Muscular dystrophy

congenital encephalomyopathy with epilepsy, chorioretinitis, basal ganglia involvement, and muscle minicores (Avoni et al) 2000;47:395

congenital muscular dystrophy: an expanding clinical syndrome (Dubowitz) 2000;47:143 (Editorial)

congenital muscular dystrophy with rigid spine syndrome: a clinical, pathological, radiological, and genetic study (Flanigan et al) 2000;47:152

fukutin protein is expressed in neurons of the normal developing human brain but is reduced in Fukuyama-type congenital muscular dystrophy brain (Saito et al) 2000;47:756

Mutation

Creutzfeldt-Jakob disease profile in patients homozygous for the PRNP E200K mutation (Simon et al) 2000;47:257

de novo mutation in the *Notch3* gene causing CADASIL (Joutel et al) 2000;47:388

differential features of patients with mutations in two COX assembly genes, *SURF-1* and *SCO2* (Sue et al) 2000;47:589

diffusion-weighted magnetic resonance imaging in boys with neural cell adhesion molecule L1 mutations and congenital hydrocephalus (Graf et al) 2000;47:113

genetic and neuroradiological heterogeneity of double cortex syndrome (Gleeson et al) 2000;47:265

hemizygous mutation of the peripheral myelin protein 22 gene associated with Charcot-Marie-Tooth disease type 1 (Numakura et al) 2000;47:101

influence of mutation type and X chromosome inactivation on Rett syndrome phenotypes (Amir et al) 2000;47:670 (Expedited publication)

"missing" tau mutation identified (Hutton) 2000;47:417 (Editorial)

MNGIE: an autosomal recessive disorder due to thymidine phosphorylase mutations (Nishino et al) 2000;47:792

mutations in the neuroserpin gene are rare in familial dementia (French Alzheimer's Disease Study Group and Fronto-Temporal Dementia Genetics Study Group) 2000;47:688 (Letter)

nonsense mutation of the *ATRX* gene causing mild mental retardation and epilepsy (Guerrini et al) 2000;47:117

novel Leu723Pro amyloid precursor protein mutation increases amyloid β 42(43) peptide levels and induces apoptosis (Kwok et al) 2000;47:249

novel missense mutations in the glycogen-branching enzyme gene in adult polyglucosan body disease (Ziemssen et al) 2000;47:536

a novel mutation at position +12 in the intron following exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto) (Yasuda et al) 2000;47:422

novel mutation of *KCNQ3* (c.925TC) in a Japanese family with benign familial neonatal convulsions (BFNC2) (Hirose et al) 2000;47:822

oxidative phosphorylation defect in the brains of carriers of the tRNA^{Leu(UUR)} A3243G mutation in a MELAS pedigree (Dubeau et al) 2000;47:179

partial deficiency of manganese superoxide dismutase exacerbates a transgenic mouse model of amyotrophic lateral sclerosis (Andreassen et al) 2000;47:447

recessive Charcot-Marie-Tooth disease (Lupski) 2000;47:6 (Editorial)

sonic hedgehog signal peptide mutation in a patient with holoprosencephaly (Kato et al) 2000;47:514

Spanish families with cerebral cavernous angioma do not bear 742C[arrow]T Hispanic-American mutation of the *KRIT1* gene (Lucas et al) 2000;47:836 (Letter)

spectrum of mutations causing end-plate acetylcholinesterase deficiency (Ohno et al) 2000;47:162

three novel mutations (G27E, insAAC, R179X) in the *ORT1* gene of Japanese patients with hyperornithinemia, hyperammonemia, and homocitrullinuria syndrome (Tsujino et al) 2000;47:624

very low levels of the mtDNA A3243G mutation associated with mitochondrial dysfunction in vivo (Chinnery et al) 2000;47:381

Myasthenia gravis

association of primary central nervous system lymphoma with long-term azathioprine therapy for myasthenia gravis? (Herrlinger et al) 2000;47:682 (Letter)

IgG from "seronegative" myasthenia gravis patients binds to a muscle cell line, TE671, but not to human acetylcholine receptor (Blaes et al) 2000;47:504

spectrum of mutations causing end-plate acetylcholinesterase deficiency (Ohno et al) 2000;47:162

Myelin

myelin widenings and MGUS-IgA: an immunoelectron based microscopic study (Vallat et al) 2000;47:808

no cytomegalovirus DNA in sera from patients with anti-MAG/SGPG antibody-associated neuropathy (Irie et al) (Letter); (Yamamoto and Yuki) (Reply) 2000;47:274

Myelin proteins

hemizygous mutation of the peripheral myelin protein 22 gene associated with Charcot-Marie-Tooth disease type 1 (Numakura et al) 2000;47:101

recessive Charcot-Marie-Tooth disease (Lupski) 2000;47:6 (Editorial)

Myoclonus

evaluation of the role of the D2 dopamine receptor in myoclonus dystonia (Klein et al) 2000;47:369

Myopathy; see Muscular diseases**Myositis**

partial laminin $\alpha 2$ chain deficiency in a patient with myopathy resembling inclusion body myositis (Di Blasi et al) 2000;47:811.

Neonate; see Infant, newborn**Neopallium; see Cerebral cortex****Nerve degeneration**

functional motor unit failure precedes neuromuscular degeneration in canine motor neuron disease (Balice-Gordon et al) 2000;47:596

Nerve endings

in vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease (Lee et al) 2000;47:493

Neural cell adhesion molecule; see Cell adhesion molecules**Neural pathways**

in vivo visualization of human neural pathways in magnetic resonance imaging (Mori et al) 2000;47:412 (Letter)

Neurites

apoE facilitates neuritic and cerebrovascular plaque formation in the APPsw mouse model of Alzheimer's disease (Holtzman et al) 2000;47:739

Neurofibrillary tangles

where in the brain does Alzheimer's disease begin? (Terry) 2000;47:421 (Editorial)

Neurofibromatosis 1

thalamic involvement in neurofibromatosis type 1: evaluation with proton magnetic resonance spectroscopic imaging (Wang et al) 2000;47:477

Neuronal ceroid-lipofuscinosis

prenatal testing for late infantile neuronal ceroid-lipofuscinosis (Berry-Kravis et al) 2000;47:254

Neuronal plasticity

levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? (Calabresi et al) 2000;47:S60
nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment (Hirsch) 2000;47:S115

Neurons

fukutin protein is expressed in neurons of the normal developing human brain but is reduced in Fukuyama-type congenital muscular dystrophy brain (Saito et al) 2000;47:756

neuronal intranuclear inclusions in spinocerebellar ataxia type 2 (Koyano et al) 2000;47:550 (Letter)

neuronal recordings in Parkinson's disease patients with dyskinetic induced by apomorphine (Lozano et al) 2000;47:S141

α -synuclein and Parkinson's disease: selective neurodegenerative effect of α -synuclein fragment on dopaminergic neurons in vitro and in vivo (Forloni et al) 2000;47:632

Neuroserpin

mutations in the neuroserpin gene are rare in familial dementia (French Alzheimer's Disease Study Group and Fronto-Temporal Dementia Genetics Study Group) 2000;47:688 (Letter)

Neurotoxins

proinflammatory cytokines and interleukin-9 exacerbate excitotoxic lesions of the newborn murine neopallium (Dommergues et al) 2000;47:54

synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine (Nath et al) 2000;47:186

Newborn; see Infant, newborn**Nitrates**

nitration of manganese superoxide dismutase in cerebrospinal fluids is a marker for peroxynitrite-mediated oxidative stress in neurodegenerative disease (Aoyama et al) 2000;47:524

Nuclear magnetic resonance

magnetic resonance spectroscopy of episodic ataxia type 2 and migraine (Montagna et al) (Letter); (Sappey-Marinier et al) (Reply) 2000;47:838

prognostic value of proton magnetic resonance spectroscopic imaging for surgical outcome in patients with intractable temporal lobe epilepsy and bilateral hippocampal atrophy (Li et al) 2000;47:195

reversible brain creatine deficiency in two sisters with normal blood creatine level (Bianchi et al) 2000;47:511
thalamic involvement in neurofibromatosis type 1: evaluation with proton magnetic resonance spectroscopic imaging (Wang et al) 2000;47:477

Nucleotides

single nucleotide polymorphism of dopamine transporter gene is associated with Parkinson's disease (Morino et al) 2000;47:528

Ornithine

three novel mutations (G27E, insAAC, R179X) in the *ORNT1* gene of Japanese patients with hyperornithinemia, hyperammonemia, and homocitrullinuria syndrome (Tsujino et al) 2000;47:624

Osler, William

William Osler: *On Chorea: on Charcot* (Goetz) 2000;47:404 (History of neurology)

Oxidative phosphorylation

oxidative phosphorylation defect in the brains of carriers of the tRNA^{Leu(UUR)} A3243G mutation in a MELAS pedigree (Dubeau et al) 2000;47:179

Paralysis, familial periodic

randomized trials of dichlorphenamide in the periodic paralyses (Tawil et al) 2000;47:46

Paraneoplastic syndromes

cytotoxic T cells in paraneoplastic cerebellar degeneration (Greenlee) 2000;47:4 (Editorial)

detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration (Albert et al) 2000;47:9

Parietal lobe

sensory tricks in cervical dystonia: perceptual dysbalance of parietal cortex modulates frontal motor programming (Naumann et al) 2000;47:322

Parkin

expression of α -synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson's disease (Solano et al) 2000;47:201

Parkinson's disease, analysis

in vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease (Lee et al) 2000;47:493
 α -synuclein-1 is present in Lewy bodies in Parkinson's disease (Wakabayashi et al) 2000;47:521

Parkinson's disease, drug therapy

levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease (Di Rocco and Werner) (Letter); (Muriel et al) (Reply) 2000;47:136

Parkinson's disease, drug therapy, complications

clinical pharmacology of levodopa-induced dyskinesia (Nutt) 2000;47:S160

clinical physiology of dopa dyskinesia (Hallett) 2000;47:S147

dopamine receptors and locomotor responses: molecular aspects (Sealfon) 2000;47:S12

dopamine-mediated gene regulation in models of Parkinson's disease (Gerfen) 2000;47:S42

dyskinesias and the subthalamic nucleus (Benabid et al) 2000;47:S189

factors influencing the onset and persistence of dyskinesia in MPTP-treated primates (Jenner) 2000;47:S90

investigating levodopa-induced dyskinesias in the parkinsonian primate (Langston et al) 2000;47:S79

levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? (Calabresi et al) 2000;47:S60

levodopa-induced dyskinesias: foreword (Olanow et al) 2000;47:S1

levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible? (Bejjani et al) 2000;47:655

medical treatment of levodopa-induced dyskinesias (Rascol) 2000;47:S179

molecular basis of levodopa-induced dyskinesias (Calon et al) 2000;47:S70

neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease (Brotchie) 2000;47:S105

neuroimaging of dyskinesia (Brooks et al) 2000;47:S154

neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine (Lozano et al) 2000;47:S141

nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment (Hirsch) 2000;47:S115

pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model (Obeso et al) 2000;47:S22

patterns of gene expression and behavior induced by chronic dopamine treatments (Canales and Graybiel) 2000;47:S53

physiologic basis of dyskinesia (Filion) 2000;47:S35

physiology of hypokinetic and hyperkinetic movement disorders: model for dyskinesia (Vitek and Giroux) 2000;47:S131

preventing levodopa-induced dyskinesias (Olanow and Obeso) 2000;47:S167

spectrum of levodopa-induced dyskinesias (Fahn) 2000;47:S2

striatal mechanisms and pathogenesis of parkinsonian signs and motor complications (Chase and Oh) 2000;47:S122

surgery for levodopa-induced dyskinesias (Lang) 2000;47:S193

Parkinson's disease, genetics

expression of α -synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson's disease (Solano et al) 2000;47:201

role of inheritance in sporadic Parkinson's disease (Hawkes) 2000;47:682 (Letter)

significant association between the tau gene A0/A0 genotype and Parkinson's disease (Pastor et al) 2000;47:242

single nucleotide polymorphism of dopamine transporter gene is associated with Parkinson's disease (Morino et al) 2000;47:528

α -synuclein and Parkinson's disease: selective neurodegenerative effect of α -synuclein fragment on dopaminergic neurons in vitro and in vivo (Forloni et al) 2000;47:632

Parkinson's disease, pathology

degeneration of the centrum median-parafascicular complex in Parkinson's disease (Henderson et al) 2000;47:345

progression in Parkinson's disease: a PET study with a dopamine transporter ligand [^{18}F]CFT (Nurmi et al) 2000;47:804

Parkinson's disease, physiopathology

joint position sense is impaired by Parkinson's disease (Zia et al) 2000;47:218

Penumbra???

penumbral tissue alkalosis in focal cerebral ischemia: relationship to energy metabolism, blood flow, and steady potential (Back et al) 2000;47:485

Perfusion magnetic resonance imaging; see Magnetic resonance imaging

Periodic paralyses; see Paralysis, familial periodic

Peripheral myelin protein; see Myelin proteins

Peroxisomes; see Microbodies

Peroxynitrite

nitration of manganese superoxide dismutase in cerebrospinal fluids is a marker for peroxynitrite-mediated oxidative stress in neurodegenerative disease (Aoyama et al) 2000;47:524

Phenylethylamines

decreased cerebrospinal fluid levels of β -phenylethylamine in patients with Rett syndrome (Saito et al) 2000;47:801

Photostimulation

neural consequences of competing stimuli in both visual hemifields: a physiological basis for visual extinction (Fink et al) 2000;47:440

Pocket Monsters episode (Harding) (Letter); (Tobimatsu et al) (Reply) 2000;47:275

Pipecolic acids

atypical Refsum disease with pipecolic aciduria and abnormal catalase distribution (Baumgartner et al) 2000;47:109

Pneumococcus

endothelin inhibition improves cerebral blood flow and is neuroprotective in pneumococcal meningitis (Pfister et al) 2000;47:329

Polyglucoses

novel missense mutations in the glycogen-branching enzyme gene in adult polyglucosan body disease (Ziemsen et al) 2000;47:536

Polymorphism

association of early-onset Alzheimer's disease with an interleukin-1 α gene polymorphism (Grimaldi et al) 2000;47:361

association of interleukin-1 gene polymorphisms with Alzheimer's disease (Nicoll et al) 2000;47:365

interleukin (IL)-1 β , IL-1 α , and IL-1 receptor antagonist gene polymorphisms in patients with temporal lobe epilepsy (Kanemoto et al) 2000;47:571

intracellular adhesion molecule-1 polymorphisms and genetic susceptibility to multiple sclerosis: additional data and meta-analysis (Killestein et al) (Letter); (Luomala et al) (Reply) 2000;47:277

Polyradiculoneuritis

clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside (Yuki et al) 2000;47:314

Polysaccharides

clinical and biochemical characteristics of congenital disorder of glycosylation: CDG-Ic, the first recognized ER defect in N-glycan synthesis (Grünewald et al) 2000; 47:776

Positron emission tomography; see Tomography, emission-computed

Potassium channels

novel mutation of *KCNQ3* (c.925TC) in a Japanese family with benign familial neonatal convulsions (BFNC2) (Hirose et al) 2000;47:822

Prealbumin

inclusion body myositis, muscle blood vessel and cardiac amyloidoses, and transthyretin Val122Ile allele (Askanas et al) 2000;47:544

Prenatal diagnosis

prenatal testing for late infantile neuronal ceroid-lipofuscinosis (Berry-Kravis et al) 2000;47:254

Primary progressive multiple sclerosis; see Multiple sclerosis

Prions

Creutzfeldt-Jakob disease profile in patients homozygous for the PRNP E200K mutation (Simon et al) 2000;47: 257

diagnosis of new variant Creutzfeldt-Jakob disease (Will et al) 2000;47:575

Progressive supranuclear palsy; see Supranuclear palsy, progressive

Proinflammatory cytokines; see Cytokines

Proprioception

joint position sense is impaired by Parkinson's disease (Zia et al) 2000;47:218

Proton magnetic resonance spectroscopy; see Nuclear magnetic resonance

Purkinje cells

new Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity (Vernino and Lennon) 2000;47:297

Quadriplegia

motor benefit from levodopa in spastic quadriplegic cerebral palsy (Brunstrom et al) 2000;47:662

Reading

impaired reading in patients with right hemianopia (Leff et al) 2000;47:171

Receptors, cholinergic

IgG from "seronegative" myasthenia gravis patients binds to a muscle cell line, TE671, but not to human acetylcholine receptor (Blaes et al) 2000;47:504

Receptors, dopamine

dopamine receptors and locomotor responses: molecular aspects (Sealfon) 2000;47:S12

evaluation of the role of the D2 dopamine receptor in myoclonus dystonia (Klein et al) 2000;47:369

levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease (Di Rocco and Werner) (Letter); (Muriel et al) (Reply) 2000;47:136

Receptors, GABA-benzodiazepine

benzodiazepine receptor binding in Huntington's disease: [¹¹C]flumazenil uptake measured using positron emission tomography (Künig et al) 2000;47:644

Receptors, interleukin

interleukin (IL)-1 β , IL-1 α , and IL-1 receptor antagonist gene polymorphisms in patients with temporal lobe epilepsy (Kanemoto et al) 2000;47:571

Receptors, transferrin

increased serum transferrin receptor concentrations in Friedreich ataxia (Wilson et al) 2000;47:659

Refsum's disease

atypical Refsum disease with pipecolic aciduria and abnormal catalase distribution (Baumgartner et al) 2000; 47:109

peroxisome 1, 2, 3 ... (Rizzo) 2000;47:281 (Editorial)
pharmacological induction of peroxisomes in peroxisome biogenesis disorders (Wei et al) 2000;47:286

Reperfusion injury

acute inflammatory demyelination in reperfusion nerve injury (Nukada et al) 2000;47:71

Retroviridae

rapid clearance of human immunodeficiency virus (HIV-1) from ventricular cerebrospinal fluid (CSF) during antiretroviral treatment (Eggers et al) 2000;47: 816

Rett syndrome

decreased cerebrospinal fluid levels of β -phenylethylamine in patients with Rett syndrome (Saito et al) 2000;47: 801

influence of mutation type and X chromosome inactivation on Rett syndrome phenotypes (Amir et al) 2000; 47:670 (Expedited publication)

Rickettsia

Chlamydia, *Rickettsia*, and antibiotic treatment of multiple sclerosis (Hopton Cann et al) (Letter); (Sriram et al) (Reply) 2000;47:408

Rigid spine syndrome

congenital muscular dystrophy with rigid spine syndrome: a clinical, pathological, radiological, and genetic study (Flanigan et al) 2000;47:152

RNA, messenger

expression of α -synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson's disease (Solano et al) 2000;47:201

RNA, transfer, leu

oxidative phosphorylation defect in the brains of carriers of the tRNA^{leu(UUR)} A3243G mutation in a MELAS pedigree (Dubeau et al) 2000;47:179

Sardinia

contribution of HLA to multiple sclerosis susceptibility in Sardinian affected sibling pairs (Marrosu et al) 2000;47: 411 (Letter)

Seizures

major depression is a risk factor for seizures in older adults (Hesdorffer et al) 2000;47:246

neonatal seizures induced persistent changes in intrinsic properties of CA1 rat hippocampal cells (Villeneuve et al) 2000;47:729

up-regulation of the metabotropic glutamate receptor mGluR4 in hippocampal neurons with reduced seizure vulnerability (Lie et al) 2000;47:26

Semantics

voxel-based morphometry study of semantic dementia: relationship between temporal lobe atrophy and semantic memory (Mummery et al) 2000;47:36

Sensorimotor stroke; see Cerebrovascular disorders

Sensory ganglionopathies; see Ganglia, spinal

Sickle cell anemia; see Anemia, sickle cell

Signal peptides

sonic hedgehog signal peptide mutation in a patient with holoprosencephaly (Kato et al) 2000;47:514

Simvastatin

simvastatin and plasma very-long-chain fatty acids in X-linked adrenoleukodystrophy (Verrips et al) 2000;47:552 (Letter)

Skin

association between migraine and cutaneous allodynia (Burstein et al) 2000;47:614

Small cell lung cancer; see Carcinoma, oat cell

Somatosensory cortex

sensory discrimination capabilities in patients with focal hand dystonia (Bara-Jimenez et al) 2000;47:377

Somatosensory evoked potentials; see Evoked potentials, somatosensory

Sonic hedgehog gene

sonic hedgehog signal peptide mutation in a patient with holoprosencephaly (Kato et al) 2000;47:514

Spain

Spanish families with cerebral cavernous angioma do not bear 742C[rightarrow]T Hispanic-American mutation of the KRIT1 gene (Lucas et al) 2000;47:836 (Letter)

Spinal muscular atrophy; see Muscular atrophy, spinal

Spin-labeled magnetic resonance imaging; see Magnetic resonance imaging

Spinocerebellar degeneration

neuronal intranuclear inclusions in spinocerebellar ataxia type 2 (Koyano et al) 2000;47:550 (Letter)

vitamin E deficiency due to chylomicron retention disease in Marinesco-Sjögren syndrome (Aguiglia et al) 2000;47:260

Stains and staining

rapid diagnosis of peroxisome biogenesis disorders by means of immunofluorescence staining of buccal smears (Zhang et al) 2000;47:836 (Letter)

Striatal neurons; see Corpus striatum

Striatum; see Corpus striatum

Stroke; see Cerebrovascular disorders

Substantia nigra

degeneration of the centré median-parafascicular complex in Parkinson's disease (Henderson et al) 2000;47:345
nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment (Hirsch) 2000;47:S115

Subthalamic nucleus

dyskinesias and the subthalamic nucleus (Benabid et al) 2000;47:S189

Supranuclear palsy, progressive

corticobasal degeneration shares a common genetic background with progressive supranuclear palsy (Di Maria et al) 2000;47:374

regional brain atrophy in progressive supranuclear palsy and Lewy body disease (Cordato et al) 2000;47:718

Synapses

levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? (Calabresi et al) 2000;47:S60

Synphilin

synphilin-1 is present in Lewy bodies in Parkinson's disease (Wakabayashi et al) 2000;47:521

Synuclein

expression of α -synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes

associated with familial Parkinson's disease (Solano et al) 2000;47:201

α -synuclein and Parkinson's disease: selective neurodegenerative effect of α -synuclein fragment on dopaminergic neurons in vitro and in vivo (Forloni et al) 2000;47:632

Tat protein; see Gene products, Tat

tau proteins

corticobasal degeneration shares a common genetic background with progressive supranuclear palsy (Di Maria et al) 2000;47:374

"missing" tau mutation identified (Hutton) 2000;47:417 (Editorial)

a novel mutation at position +12 in the intron following exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto) (Yasuda et al) 2000;47:422
significant association between the tau gene A0/A0 genotype and Parkinson's disease (Pastor et al) 2000;47:242

Television

Pocket Monsters episode (Harding) (Letter); (Tobimatsu et al) (Reply) 2000;47:275

Temporal lobe

verbal fluency activates the left medial temporal lobe: a functional magnetic resonance study (Pihlaja-mäki et al) 2000;47:470

voxel-based morphometry study of semantic dementia: relationship between temporal lobe atrophy and semantic memory (Mummery et al) 2000;47:36

Temporal lobe epilepsy; see Epilepsy, temporal lobe

Thalamic nuclei

degeneration of the centré median-parafascicular complex in Parkinson's disease (Henderson et al) 2000;47:345

Thalamus

thalamic involvement in neurofibromatosis type 1: evaluation with proton magnetic resonance spectroscopic imaging (Wang et al) 2000;47:477

Thrombolytic therapy

thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging (Kidwell et al) 2000;47:462

Thymidine

MNGIE: an autosomal recessive disorder due to thymidine phosphorylase mutations (Nishino et al) 2000;47:792

T-lymphocytes

cytotoxic T cells in paraneoplastic cerebellar degeneration (Greenlee) 2000;47:4 (Editorial)

detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration (Albert et al) 2000;47:9

heterogeneity of T-lymphocyte function in primary progressive multiple sclerosis: relation to magnetic resonance imaging lesion volume (Prat et al) 2000;47:234

increased numbers of CCR5⁺ interferon- γ and tumor necrosis factor- α -secreting T lymphocytes in multiple sclerosis patients (Strunk et al) 2000;47:269

Tomography, emission-computed

benzodiazepine receptor binding in Huntington's disease: [¹¹C]flumazenil uptake measured using positron emission tomography (Künig et al) 2000;47:644

in vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease (Lee et al) 2000;47:493
neuroimaging of dyskinesia (Brooks et al) 2000;47:S154

progression in Parkinson's disease: a PET study with a dopamine transporter ligand [¹⁸F]CFT (Nurmi et al) 2000;47:804

Topiramate

topiramate and essential tremor (Gálvez-Jiménez and Hargrave) 2000;47:837 (Letter)

Transferrin

increased serum transferrin receptor concentrations in Friedreich ataxia (Wilson et al) 2000;47:659

Transthyretin; *see* Prealbumin

Tremor

topiramate and essential tremor (Gálvez-Jiménez and Hargrave) 2000;47:837 (Letter)

tRNA^{leu}; *see* RNA, transfer, leu

Tumor necrosis factor

increased numbers of CCR5⁺ interferon- γ and tumor necrosis factor- α -secreting T lymphocytes in multiple sclerosis patients (Strunk et al) 2000;47:269

Twins

role of inheritance in sporadic Parkinson's disease (Hawkes) 2000;47:682 (Letter)

Type I interferon; *see* Interferon type I

Ubiquitin

expression of α -synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson's disease (Solano et al) 2000;47:201

Up-regulation

up-regulation of the metabotropic glutamate receptor mGluR4 in hippocampal neurons with reduced seizure vulnerability (Lie et al) 2000;47:26

Vacuoles

X-linked vacuolar myopathies: two separate loci and refined genetic mapping (Auranen et al) 2000;47:666

Valproic acid

valproate for girls with epilepsy (Balen and Genton) (Letter); (Isojärvi et al) (Reply) 2000;47:550

Varicella; *see* Chickenpox

Vein of Galen; *see* Cerebral veins

Verbal behavior

verbal fluency activates the left medial temporal lobe: a

functional magnetic resonance imaging study (Pihlajamäki et al) 2000;47:470

Very-long-chain fatty acids; *see* Fatty acids

Vision disorders

neural consequences of competing stimuli in both visual hemifields: a physiological basis for visual extinction (Fink et al) 2000;47:440

Visual cortex

neural consequences of competing stimuli in both visual hemifields: a physiological basis for visual extinction (Fink et al) 2000;47:440

Vitamin E deficiency

vitamin E deficiency due to chylomicron retention disease in Marinesco-Sjögren syndrome (Aguiglia et al) 2000; 47:260

Weight loss

higher sedentary energy expenditure in patients with Huntington's disease (Pratley et al) 2000;47:64

White matter

age-related white matter changes and cognitive impairment (Inzitari) 2000;47:141 (Editorial)

cerebral white matter lesions and cognitive function: the Rotterdam Scan Study (de Groot et al) 2000;47:145 quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis (Evangeliou et al) 2000;47:391

X chromosome

influence of mutation type and X chromosome inactivation on Rett syndrome phenotypes (Amir et al) 2000; 47:670 (Expedited publication)

simvastatin and plasma very-long-chain fatty acids in X-linked adrenoleukodystrophy (Verrrips et al) 2000;47: 552 (Letter)

X-linked vacuolar myopathies: two separate loci and refined genetic mapping (Auranen et al) 2000;47:666

Zellweger syndrome

peroxisome 1, 2, 3 ... (Rizzo) 2000;47:281 (Editorial)

pharmacological induction of peroxisomes in peroxisome biogenesis disorders (Wei et al) 2000;47:286

